10 November 2021
EMA/621477/2021 Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 13-16 September 2021

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Disclaimers

Some of the information contained in set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, the minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions. See September 2021 CHMP minutes for the list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session held 13 - 16 September 2021.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 17 or more members were present remotely). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

CHMP agenda for 13-16 September 2021

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 19-22 July 2021 plenary meeting and 16-19 August 2021 written procedure.

Minutes from PRocedural and Organisational Matters (PROM) meeting held on 06 September 2021.

The CHMP adopted the CHMP minutes for 19 – 22 July and 16 – 19 August 2021.

The CHMP adopted the minutes from the PROM meeting held on 06 September 2021.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. abrocitinib - EMEA/H/C/005452

Indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

Scope: Oral explanation

Action: Oral explanation to be held on 14 September 2021 at 14:00

List of Outstanding Issues adopted on 24.06.2021. List of Questions adopted on 28.01.2021.

An oral explanation was held on 14 September 2021. The presentation by the applicant focused on the clinical data in support of the application.

See 3.2

2.1.2. Gavreto - pralsetinib - EMEA/H/C/005413

Roche Registration GmbH; treatment of non-small cell lung cancer (NSCLC)

Scope: Possible oral explanation

Action: Oral explanation to be held on 15 September 2021 at 09:30

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 24.06.2021, 22.04.2021, 28.01.2021. List of Questions adopted on 17.09.2020.

The CHMP agreed that no oral explanation was needed this time.

See 3.1

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.3.1. Presence of the nitrosamine N-nitroso-varenicline in Champix – EMEA/H/C/000699

Pfizer Europe MA EEIG

Rapporteur: Kirstine Moll Harboe, Co-Rapporteur: Johann Lodewijk Hillege

Scope: Oral explanation

Action: Oral explanation to be held on 14 September 2021 at 16:00

An oral explanation was held on 14 September 2021.

2.3.2. Veklury - remdesivir - EMEA/H/C/005622/II/0016

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová

Scope: "Extension of indication to include treatment of adults with pneumonia not requiring supplemental oxygen (moderate COVID-19), based on Part A of study GS-US-540-5774, a Phase 3, randomized, open-label, multicenter study comparing 2 RDV regimens (5 days and 10 days) versus standard of care in 584 participants with moderate COVID 19, and study CO US 540 5776 [Adaptive COVID-19 Treatment Trial (ACTT) 1, a National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Phase 3, randomized, double blind, placebo controlled, multicenter study]. As a consequence, sections 4.1 and 5.1 of the SmPC are being updated, and the Package Leaflet is updated in accordance. A revised version 1.2 of the RMP has also been submitted."

Scope: Oral explanation

Action: Oral explanation to be held on 14 September 2021 at 11:00

Request for Supplementary Information adopted on 20.05.2021.

The CHMP agreed that no oral explanation was needed this time.

See 5.1

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Artesunate Amivas - artesunate - Orphan - EMEA/H/C/005550

Amivas Ireland Ltd; treatment of malaria

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 24.06.2021. List of Questions adopted on 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that artesunate is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.2. Brukinsa - zanubrutinib - Orphan - EMEA/H/C/004978

BeiGene Ireland Ltd; treatment of Waldenström's macroglobulinaemia (WM)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 24.06.2021, 22.04.2021. List of Questions adopted on 15.10.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

The CHMP adopted a derogation report.

3.1.3. Gavreto - pralsetinib - EMEA/H/C/005413

Roche Registration GmbH; treatment of non-small cell lung cancer (NSCLC)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 24.06.2021, 22.04.2021, 28.01.2021. List of Questions adopted on 17.09.2020.

The CHMP agreed that no oral explanation was needed this time.

See 2.1

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considers that pralsetinib is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 15.09.2021

The summary of opinion was circulated for information.

3.1.4. Hukyndra - adalimumab - EMEA/H/C/005548

STADA Arzneimittel AG; treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis, paediatric uveitis

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 15 September 2021.

The summary of opinion was circulated for information.

3.1.5. Libmyris - adalimumab - EMEA/H/C/005947

STADA Arzneimittel AG; treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis, paediatric uveitis

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC), Duplicate of Hukyndra

List of Outstanding Issues adopted on 22.07.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 15 September 2021.

The summary of opinion was circulated for information.

3.1.6. Qinlock - ripretinib - Orphan - EMEA/H/C/005614

Deciphera Pharmaceuticals (Netherlands) B.V.; treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 24.06.2021. List of Questions adopted on 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 14 September 2021.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.7. Raylumis - tanezumab - EMEA/H/C/005189

Pfizer Europe MA EEIG; treatment of moderate to severe chronic pain associated with osteoarthritis (OA) in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or an opioid is ineffective, not tolerated or inappropriate

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC

List of Outstanding Issues adopted on 22.07.2021, 20.05.2021, 28.01.2021. List of Questions adopted on 23.07.2020.

The CHMP adopted a negative opinion by consensus, recommending the refusal of the marketing authorisation.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The refusal questions and answers document was circulated for information.

3.1.8. Rivaroxaban Mylan - rivaroxaban - EMEA/H/C/005600

Mylan Ireland Limited; Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors. Treatment of deep vein thrombosis and pulmonary embolism and prevention of recurrent DVT and PE in adults. Prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 16 September 2021.

The summary of opinion was circulated for information.

3.1.9. Sugammadex Mylan - sugammadex - EMEA/H/C/005403

Mylan Ireland Limited; treatment of neuromuscular blockade induced by rocuronium or vecuronium

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Bridion

List of Outstanding Issues adopted on 20.05.2021. List of Questions adopted on 17.09.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.10. Vumerity - diroximel fumarate - EMEA/H/C/005437

Biogen Netherlands B.V.; treatment of relapsing remitting multiple sclerosis

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 22.04.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. pegcetacoplan - Orphan - EMEA/H/C/005553

Apellis Ireland Limited; paroxysmal nocturnal haemoglobinuria (PNH)

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 24.06.2021. List of Questions adopted on 28.01.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.2. abrocitinib - EMEA/H/C/005452

Indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

Scope: Oral explanation

Action: Oral explanation to be held on 14 September 2021 at 14:00

List of Outstanding Issues adopted on 24.06.2021. List of Questions adopted on

28.01.2021.

See 2.1

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.3. artesunate - Orphan - EMEA/H/C/005718

B And O Pharm; Treatment of severe malaria

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 22.04.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.4. lonapegsomatropin - Orphan - EMEA/H/C/005367

Ascendis Pharma Endocrinology Division A/S; Treatment of growth hormone deficiency

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 24.06.2021. List of Questions adopted on 28.01.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.5. hepatitis B surface antigen - EMEA/H/C/005466

indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.04.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.6. finerenone - EMEA/H/C/005200

delay progression of kidney disease, reduce the risk of cardiovascular mortality and morbidity

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.03.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.7. lonafarnib - Orphan - EMEA/H/C/005271

EigerBio Europe Limited; treatment of Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 23.07.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.8. sotorasib - EMEA/H/C/005522

treatment of locally advanced or metastatic non-small cell lung cancer

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 20.05.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.9. arimoclomol - Orphan - EMEA/H/C/005203

Orphazyme A/S; treatment of Niemann-Pick disease type C (NPC)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.03.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues as

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.10. enfortumab vedotin - EMEA/H/C/005392

Accelerated assessment

treatment of locally advanced (LA) or metastatic urothelial cancer (mUC)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.06.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.11. lasmiditan - EMEA/H/C/005332

acute treatment of migraine with or without aura in adults

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 25.03.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.12. amivantamab - EMEA/H/C/005454

for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 20.05.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.13. sitagliptin - EMEA/H/C/005598

treatment of type 2 diabetes mellitus

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 20.05.2021. List of Questions adopted on 17.09.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.14. tepotinib - EMEA/H/C/005524

treatment of advanced non-small cell lung cancer

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.03.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed to consult the SAG Oncology and adopted a list of questions to the experts.

3.2.15. sacituzumab govitecan - EMEA/H/C/005182

Accelerated assessment

treatment of unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.06.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.16. inebilizumab - Orphan - EMEA/H/C/005818

Viela Bio; indicated for the treatment of adults with neuromyelitis optica spectrum disorders

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.04.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.17. pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477

immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.04.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.18. vildagliptin / metformin hydrochloride - EMEA/H/C/005738

treatment of type 2 diabetes mellitus

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.04.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.19. eptinezumab - EMEA/H/C/005287

Indicated for the prophylaxis of migraine in adults

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.04.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.20. glucarpidase - Orphan - EMEA/H/C/005467

Protherics Medicines Development Europe B.V.; treatment of patients at risk of methotrexate toxicity

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 24.06.2021. List of Questions adopted on 10.12.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.21. linzagolix choline - EMEA/H/C/005442

for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.04.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. amifampridine - EMEA/H/C/005839

treatment of Lambert-Eaton Myasthenic Syndrome

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. ciltacabtagene autoleucel - Orphan - ATMP - EMEA/H/C/005095

Accelerated assessment

Janssen-Cilag International NV; treatment of multiple myeloma

Scope: List of questions

Action: For information

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. budesonide, micronised - Orphan - EMEA/H/C/005653

Accelerated assessment

Calliditas Therapeutics AB; treatment of primary immunoglobulin A (IgA) nephropathy

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application. The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. melphalan flufenamide - Orphan - EMEA/H/C/005681

Oncopeptides AB; treatment of multiple myeloma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.5. palovarotene - Orphan - EMEA/H/C/004867

Ipsen Pharma; Treatment of fibrodysplasia ossificans progressiva

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. iodine (131i) omburtamab - Orphan - EMEA/H/C/005499

Y-Mabs Therapeutics A/S; treatment of neuroblastoma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.7. pirfenidone - EMEA/H/C/005873

indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.8. sitagliptin / metformin hydrochloride - EMEA/H/C/005850

treatment of type 2 diabetes mellitus

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.9. ranibizumab - EMEA/H/C/005610

treatment of neovascular age-related macular degeneration in adults

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application including

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.10. capmatinib - EMEA/H/C/004845

treatment of non-small cell lung cancer (NSCLC)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.11. thalidomide - EMEA/H/C/005715

treatment of multiple myeloma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.12. insulin aspart - EMEA/H/C/005635

treatment of diabetes mellitus

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. teriparatide - EMEA/H/C/005793

treatment of osteoporosis

Scope: Letter from the applicant dated 22 July 2021 requesting an extension to the clock stop to respond to the list of questions adopted in May 2021.

Action: For adoption

List of Questions adopted on 20.05.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in May 2021.

3.4.2. autologous glioma tumor cells, inactivated / autologous glioma tumor cell lysates, inactivated / allogeneic glioma tumor cells, inactivated / allogeneic glioma tumor cell lysates, inactivated - Orphan - ATMP - EMEA/H/C/003693

Epitopoietic Research Corporation-Belgium (E.R.C.); treatment of glioma

Scope: Letter from the applicant dated 26 August 2021 requesting an extension to the clock stop to respond to the list of outstanding issues adopted on in July 2021.

Action: For information

List of Outstanding Issues adopted on 16.07.2021. List of Questions adopted on 22.01.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the respond to the list of outstanding issues adopted in July 2021.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Nouryant - istradefylline - EMEA/H/C/005308

Kyowa Kirin Holdings B.V.; indicated as an adjunctive treatment to levodopa-based regimens in patients with Parkinson's disease

Scope: appointment of re-examination rapporteurs, start of procedure

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 22.07.2021. List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 30.04.2020.

The CHMP adopted the draft timetable.

The CHMP appointed a Re-examination Rapporteur and a re-examination Co-Rapporteur.

3.5.2. Nexviadyme – avalglucosidase alfa – Orphan – EMEA/H/C/005501

Genzyme Europe BV; for long-term enzyme replacement therapy for the treatment of patients with Pompe disease.

Scope: appointment of re-examination rapporteurs, start of procedure

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

The CHMP adopted the draft timetable.

The CHMP appointed a Re-examination Rapporteur and a re-examination Co-Rapporteur.

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

3.7.1. Oportuzumab monatox DLRC Pharma Services - oportuzumab monatox - EMEA/H/C/005730

DLRC Pharma Services Ltd; Treatment and prevention of recurrence of carcinoma-in-situ (CIS) of the urinary bladder and prevention of recurrence of high-grade Ta and/or T1 papillary tumours

Scope: Withdrawal of marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of questions adopted on 22.07.2021.

The CHMP noted the withdrawal of initial marketing authorisation application

3.7.2. Livmarli - maralixibat - Orphan - EMEA/H/C/005551

FGK Representative Service GmbH; Treatment of Progressive Familial Intrahepatic Cholestasis Type 2

Scope: Withdrawal of marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of questions adopted on 25.03.2021.

The CHMP noted the withdrawal of initial marketing authorisation application

3.7.3. Teriparatide Cinnagen - teriparatide - EMEA/H/C/005543

CinnaGen Co, Unipessoal LDA; treatment of osteoporosis

Scope: Withdrawal of marketing authorisation application

Action: For information

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Questions adopted on 25.03.2021.

The CHMP noted the withdrawal of initial marketing authorisation application

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Akynzeo - fosnetupitant / netupitant / palonosetron - EMEA/H/C/003728/X/0031

Helsinn Birex Pharmaceuticals Limited

Rapporteur: Peter Kiely, PRAC Rapporteur: Ilaria Baldelli

Scope: "Extension application to introduce a new pharmaceutical form (concentrate for solution for infusion)."

Action: For adoption

List of Outstanding Issues adopted on 24.06.2021. List of Questions adopted on 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.1.2. Lacosamide Accord - lacosamide - EMEA/H/C/004443/X/0007

Accord Healthcare S.L.U.

Rapporteur: John Joseph Borg, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to introduce a new pharmaceutical form (solution for infusion), a new strength (10 mg/ml) and a new route of administration (intravenous use)."

Action: For adoption

List of Outstanding Issues adopted on 22.07.2021, 12.11.2020. List of Questions adopted on 26.03.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The CHMP adopted the similarity assessment report.

4.1.3. Byannli (previously Paliperidone Janssen-Cilag International) - paliperidone - EMEA/H/C/005486/X/0002/G

Janssen-Cilag International N.V.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to introduce two new strengths of 700 mg and 1000 mg prolonged-release suspension for injection, grouped with the following variations:
A.2.a - To change the (invented) name of the medicinal product from Paliperidone Janssen-Cilag International to BYANNLI
A.7
6 x C.I.7.b. - To delete the 25 mg, 50 mg, 75 mg, 100 mg and 150 mg/100 mg strengths from the Paliperidone Janssen-Cilag marketing authorisation (EU/1/20/1453/001-006)."

Action: For adoption

List of Outstanding Issues adopted on 22.07.2021. List of Questions adopted on 22.04.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Adynovi - rurioctocog alfa pegol - EMEA/H/C/004195/X/0018

Baxalta Innovations GmbH

Rapporteur: Andrea Laslop, PRAC Rapporteur: Menno van der Elst

Scope: "Extension application to add a new strength of 3000 IU for RURIOCTOCOG ALFA PEGOL powder and solvent for solution for injection, for intravenous use.
Furthermore, the MAH took the opportunity to include editorial changes to update the naming convention from BAX855 to rurioctocog alfa pegol throughout the section and

removed the reference to Baxalta as well as update table numbering throughout the documents in module 3. Furthermore, change omitted from the dossier following approval of variations EMEA/H/C/004195/IB/0004/G and EMEA/H/C/004195/IB/0015/G were also included."

Action: For adoption

List of Questions adopted on 22.04.2021.

The Committee discussed the issues identified in this application relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.2. Nuwiq - simoctocog alfa - EMEA/H/C/002813/X/0042

Octapharma AB

Rapporteur: Jan Mueller-Berghaus

Scope: "Extension application to add a new strength of 1500 IU for simoctocog alfa powder and solvent for solution for injection, for Intravenous use.
The marketing authorisation holder took the opportunity to align the PI to the latest QRD template (version 10.2)."

Action: For adoption

List of Questions adopted on 24.06.2021.

The Committee discussed the issues identified in this application relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.3. Xeljanz - tofacitinib - EMEA/H/C/004214/X/0030/G

Pfizer Europe MA EEIG

Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to add a new strength (22 mg prolonged-release tablet) grouped with a type II variation C.I.4: Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of Xeljanz 11 mg prolonged-release tablets SmPC in order to include the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent; as an alternative to the immediate release film-coated tablets; section 4.2 of Xeljanz film-coated tablets is also updated to include switching with the prolonged-release tablet in the treatment of UC. The Package Leaflet is updated accordingly. The RMP version 15.1 has also been submitted."

Letter from the applicant dated 08 September 2021 requesting an extension to the clock stop to respond to the list of outstanding issues.

Action: For adoption

List of Questions adopted on 25.02.2021.

The Committee discussed the issues identified in this application relating to quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Mayzent - siponimod - EMEA/H/C/004712/X/0007

Novartis Europharm Limited

Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension application to add a new strength of 1 mg film-coated tablet.
The RMP (version 3.0) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application relating to quality aspects as well as the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.2. Nucala - mepolizumab - EMEA/H/C/003860/X/0042

GlaxoSmithKline Trading Services Limited

Rapporteur: Peter Kiely, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension application to introduce a new strength of 40 mg for Nucala solution for injection in a pre-filled syringe for subcutaneous use to be used in children aged 6 to 11 years."

Action: For adoption

The Committee discussed the issues identified in this application relating to quality and clinical aspects as well as the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.3. Xofluza - baloxavir marboxil - EMEA/H/C/004974/X/0003/G

Roche Registration GmbH

Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Sonja Hrabcik

Scope: "Extension application to add a new strength of 80 mg grouped with a type IB variation to add a new pack size for 40 mg strength.

The RMP (version 1.2) is updated in accordance.
Furthermore, the PI is being brought in line with the QRD template version 10.2 to update the local representatives with "United Kingdom (Northern Ireland) ".”

Action: For adoption

The Committee discussed the issues identified in this application relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.4. Yuflyma - adalimumab - EMEA/H/C/005188/X/0005

Celltrion Healthcare Hungary Kft.

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Ulla Wändel Liminga

Scope: “Extension application to introduce a new strengths of 80 mg solution for injection. Version 1.1 of the RMP has also been submitted.”

Action: For adoption

The Committee discussed the issues identified in this application relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Briviact - brivaracetam - EMEA/H/C/003898/II/0032/G

UCB Pharma S.A.

Rapporteur: Filip Josephson, PRAC Rapporteur: Adam Przybylkowski

Scope: “- Extension of indication to include patients from 1 month to 4 years of age for the Briviact treatment, as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are

updated. The RMP version 8.0 has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.2 and the MAH took the opportunity to implement minor editorial updates.
- (B.II.f.1.b.2)
- (B.IV.1.a.1)

The Package Leaflet and Labelling are updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021.

The Committee discussed the issues identified in this application relating to clinical aspects.The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.2. Firmagon - degarelix - EMEA/H/C/000986/II/0039/G

Ferring Pharmaceuticals A/S

Rapporteur: Alexandre Moreau

Scope: "Extension of indications to include:
- Extension of indication to include treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance.
- Extension of indication to include treatment. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 25.03.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.3. Jyseleca - filgotinib - EMEA/H/C/005113/II/0001

Gilead Sciences Ireland UC

Rapporteur: Kristina Dunder, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of indication to include the treatment of active ulcerative colitis in adults patients for Jyseleca. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 5.3 of the SmPC and the Package Leaflet are updated accordingly. The RMP is updated to Version 4.0. In addition, the Marketing authorisation holder (MAH) took the opportunity to do minor

updates to the Annex II and to implement minor editorial changes in the SmPC and Package Leaflet.

The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 20.05.2021, 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.4. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0099

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for Keytruda to include in combination with chemotherapy, treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 31.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021, 25.03.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.5. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0104

Merck Sharp & Dohme B.V.

Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for Keytruda to include in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC); as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in

accordance. Version 32.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.6. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0105

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma in adults who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 33.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.7. Kisplyx - lenvatinib - EMEA/H/C/004224/II/0045

Eisai GmbH

Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: David Olsen

Scope: "Extension of indication for Kisplyx to include in combination with pembrolizumab first line treatment of adults with advanced renal cell carcinoma (RCC); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13 of the RMP has also been submitted. In addition, the Marketing authorisation holder took the opportunity to update the list of local representatives in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.8. Lenvima - lenvatinib - EMEA/H/C/003727/II/0042

Eisai GmbH

Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Annika Folin

Scope: "Extension of indication to include lenvatinib in combination with pembrolizumab for the treatment of adult patients with advanced endometrial carcinoma (EC) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 14.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to make minor editorial changes to the SmPC and update the list of local representatives in the Package Leaflet in line with the latest QRD template version 10.2." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.9. Lorviqua - lorlatinib - EMEA/H/C/004646/II/0015

Pfizer Europe MA EEIG

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of indication to include the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor based on results from the phase III randomised CROWN (1006) study listed as a specific obligation (SOB) in the Annex II; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package leaflet is updated accordingly. Version 3.0 of the RMP has also been submitted. In addition, the applicant proposes to downgrade the specific obligation to conduct a single arm study in patients who progressed after alectinib or ceritinib to a recommendation and convert the conditional MA to a full MA."

Action: For adoption

Request for Supplementary Information adopted on 20.05.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.10. Noxafil - posaconazole - EMEA/H/C/000610/II/0062

Merck Sharp & Dohme B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Extension of indication to include primary treatment of invasive aspergillosis in adults and adolescents from 13 years of age for Noxafil gastroresistant tablet and concentrate for solution for infusion as result of conclusion of study P069 (a Phase 3

Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 16.2 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 22.07.2021, 25.03.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.11. Nucala - mepolizumab - EMEA/H/C/003860/II/0035

GlaxoSmithKline Trading Services Limited

Rapporteur: Peter Kiely, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for Nucala (mepolizumab). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7 of the RMP has also been submitted. In addition, the marketing authorisation holder took the opportunity to update the local (IT) representative in the PL."

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021, 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.12. Nucala - mepolizumab - EMEA/H/C/003860/II/0036/G

GlaxoSmithKline Trading Services Limited

Rapporteur: Peter Kiely, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include Eosinophilic Granulomatosis with Polyangiitis (EGPA) to Nucala (mepolizumab); as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7 of the RMP

has also been submitted.
In addition, the marketing authorisation holder took the opportunity to update the local representative (IT) in the PL.
2 Variations: Type I B.11.e.5.a.2 - To add a new pack size for pre-filled pens for Nucala, 100 mg/ml, solution for injection and another pack size for pre-filled syringes for Nucala, 100 mg/ml, solution for injection.
As a consequence, sections 6.5 and 8 of the SmPCs and section 6 of the PLs are updated accordingly.
Annex IIIA is also being updated to include information relating to the new pack sizes.
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004) for EGPA"

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021, 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.13. Nucala - mepolizumab - EMEA/H/C/003860/II/0037

GlaxoSmithKline Trading Services Limited

Rapporteur: Peter Kiely, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include hypereosinophilic syndrome (HES) for Nucala (mepolizumab); as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 (in addition 6.6 for the powder for solution for injection ONLY) of the SmPC. The Package Leaflet is updated in accordance. Version 7 of the RMP has also been submitted.
In addition, the marketing authorisation holder took the opportunity to update the local representative (IT) in the PL."

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021, 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.14. Opdivo - nivolumab - EMEA/H/C/003985/II/0096

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to use OPDIVO (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy, in first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5 (Study CA209649); as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 21.2 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 22.07.2021, 25.03.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.15. Tecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - Orphan - ATMP - EMEA/H/C/005102/II/0008/G

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Group of variations including an extension of indication to include treatment of adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (B-ALL) for Tecartus and a type IB variation to change the Drug Product Dose specification for the new indication. As a consequence, sections 2.2, 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 1.1 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.16. Tecfidera - dimethyl fumarate - EMEA/H/C/002601/II/0073

Biogen Netherlands B.V.

Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber

Scope: "C.I.6 (Extension of indication) type II Art.29 Extension of indication to include treatment of relapsing remitting multiple sclerosis (RRMS) in paediatrics patients from 10 years of age and over; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.3 are updated. The Package Leaflet is updated in accordance.
The MAH is requesting an extension of the market protection of one additional year in line with the guidance on elements required to support the significant clinical benefit in comparison with existing therapies of a new therapeutic indication in accordance with Article 14(11) of Regulation (EC) 726/2004.
Version 11.4 of the RMP has also been submitted to update the RMP (parts I-IV) based on study 109MS306 data supporting the request for a paediatric indication and the Applicant took the opportunity to update the RMP with the most updated data (Part II modules SIV, SV and SVII). " Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.17. Teysuno - tegafur / gimeracil / oteracil - EMEA/H/C/001242/II/0045

Nordic Group B.V.

Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment of metastatic colorectal cancer in adult patients where it is not possible to initiate or continue treatment with another fluoropyrimidine. As a consequence, sections 4.1, 4.2, 4.3, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 28.01.2021.

The Committee discussed the issues identified in this application, relating to non-clinical and clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.18. Tookad - padeliporfin - EMEA/H/C/004182/II/0013

STEBA Biotech S.A

Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maia Uusküla

Scope: "Modification of the wording of the existing indication. The new wording will be the treatment of adult patients with previously untreated, unilateral, low-risk, adenocarcinoma

of the prostate with a life expectancy ≥ 10 years and clinical stage T1c or T2a, ISUP Grade Group ≤ 2, based on high-resolution biopsy strategies, PSA ≤ 10 ng/mL, Low core positivity for TOOKAD; as a consequence, section 4.1 of the SmPC is updated. Version 6.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 20.05.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.19. Veklury - remdesivir - EMEA/H/C/005622/II/0016

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová

Scope: "Extension of indication to include treatment of adults with pneumonia not requiring supplemental oxygen (moderate COVID-19), based on Part A of study GS-US-540-5774, a Phase 3, randomized, open-label, multicenter study comparing 2 RDV regimens (5 days and 10 days) versus standard of care in 584 participants with moderate COVID 19, and study CO US 540 5776 [Adaptive COVID-19 Treatment Trial (ACTT) 1, a National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Phase 3, randomized, double blind, placebo controlled, multicenter study]. As a consequence, sections 4.1 and 5.1 of the SmPC are being updated, and the Package Leaflet is updated in accordance. A revised version 1.2 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 20.05.2021.

The CHMP agreed that no oral explanation was needed this time.

See 2.3

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.20. Xalkori - crizotinib - EMEA/H/C/002489/II/0072

Pfizer Europe MA EEIG

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Extension of indication to include treatment of paediatric patients (age ≥ 6 to < 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumour (IMT) for Xalkori based on the results from studies ADVL0912 and A8081013; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the ATC code for crizotinib. Moreover, the MAH took the

opportunity to implement a minor change in the list of local representatives in the Package Leaflet."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.21. Zepatier - elbasvir / grazoprevir - EMEA/H/C/004126/II/0029

Merck Sharp & Dohme B.V.

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension of indication to include treatment of chronic hepatitis C (CHC) in paediatric patients 12 years of age and older who weigh at least 30 kg for Zepatier; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.22. WS1953 Segluromet - ertugliflozin / metformin hydrochloride - EMEA/H/C/004314/WS1953/0012 Steglatro - ertugliflozin - EMEA/H/C/004315/WS1953/0013

Merck Sharp & Dohme B.V.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst

Scope: "Update of sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC of Steglatro and Segluromet in order to modify the indication, update posology recommendations and include efficacy and safety information based on final results from the VERTIS CV study (protocol 8835-004/B1521021) listed as a category 3 study in the RMP. This is a multi-centre, multi-national, randomised, double-blind, placebo-controlled study to evaluate the effect of ertugliflozin on cardiovascular risk in adult patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021, 25.02.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.23. WS2049/G
Lacosamide UCB - lacosamide - EMEA/H/C/005243/WS2049/0009/G
Vimpat - lacosamide - EMEA/H/C/000863/WS2049/0091/G

UCB Pharma S.A.

Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include patients from 1 month to 4 years of age for treatment of partial-onset seizures with or without secondary generalisation as monotherapy and adjunctive therapy for Vimpat/Lacosamide USB. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. Version 16.0 of the RMP has also been submitted.
B.IV.1.a.1 -
B.II.f.1.b.2 -
The Package Leaflet and labelling are updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

6.2. Update of Ancillary medicinal substances in medical devices

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. tabelecleucel - Orphan - H0004577

ATARA Biotherapeutics Ireland Limited, Treatment of patients with Epstein-Barr positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is considered inappropriate.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.2. mosunetuzumab – H0005680

indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.3. encequidar and paclitaxel – H0005999

indicated for the treatment of adult patients with advanced breast cancer

Scope: Call for nomination of a CHMP Sponsor in relation to an application for a combination pack

Action: For informationThe CHMP noted call for nomination of a CHMP Sponsor in relation to an application for a combination pack.

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

The CHMP noted the list of applications received.

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 5 recommendations for eligibility to PRIME: 1 were granted and 4 were denied.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Cosentyx - secukinumab - EMEA/H/C/003729/II/0076

Novartis Europharm Limited

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia

Scope: C.I.4 - Update of sections 4.2 and 5.1 of the SmPC in order to introduce a new posology regimen for adult plaque psoriasis patients and psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis based on the final results study CAIN457A2324 and exposure-response modelling; this is a randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety,

and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 kg or higher with moderate to severe chronic plaque-type psoriasis; the Package Leaflet is updated accordingly. The RMP version 9.0 has also been submitted.

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects as well as the RMP.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

9.1.2. Bosulif - bosutinib - EMEA/H/C/002373/II/0050/G

Pfizer Europe MA EEIG

Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber

Scope: "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to reflect results from the studies B1871039 (SOB) and B1871040 (category 3); study B1871039 is a Phase 4 Safety and Efficacy Study of Bosutinib in Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukaemia Previously Treated With One or More Tyrosine Kinase Inhibitors and study B1871040 is An Open-Label Bosutinib Treatment Extension Study for Subjects With Chronic Myeloid Leukaemia (CML) who Have Previously Participated in Bosutinib Studies B1871006 or B1871008. The Package Leaflet is updated accordingly. The MAH request deletion of the SOB from annex II of the PI and request consideration for switch of the Conditional Marketing Authorisation to a full Marketing Authorisation. The RMP version 6.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives for Belgium, Luxemburg, Germany and Northern Island in the Package Leaflet. The MAH is also asking the deletion of the product from the additional monitoring list."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects as well as the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.3. Presence of the nitrosamine N-nitroso-varenicline in Champix – EMEA/H/C/000699

Pfizer Europe MA EEIG

Rapporteur: Kirstine Moll Harboe, Co-Rapporteur: Johann Lodewijk Hillege

Scope: case of presence on a novel nitrosamine in Champix exceeding the safety limit

Action: Oral explanation to be held on 14 September 2021 at 16:00

See 2.3

The CHMP adopted Quality Defect report concluding that batches of Champix (varenicline) that were found to contain levels of N-nitroso-varenicline (NNV) above the acceptable level of intake set for the EU are being recalled.

9.1.4. Jardiance - empagliflozin - EMEA/H/C/002677/II/0057

Boehringer Ingelheim International GmbH

Rapporteur: Johann Lodewijk Hillege

Scope: "Update of sections 4.2 and 4.4 of the SmPC to lower the renal threshold for initiation and use of empagliflozin depending on eGFR, and of the section 5.1 wording about endpoints with reference to EMPA-REG OUTCOME study. The PL is updated accordingly."

Action: For adoption
Request for Supplementary Information adopted on 24.06.2021, 25.03.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

9.1.5. Kanuma - sebelipase alfa - EMEA/H/C/004004/II/0032

Alexion Europe SAS

Rapporteur: Karin Janssen van Doorn

Scope: "Update of section 4.2 of the SmPC in order to introduce a new posology regimen (higher starting dose of 3 mg/kg once weekly) based on cumulative data from clinical studies and real-world clinical practice for patients with Rapidly Progressive LAL deficiency presenting within the first six months of life. Consequently, the dosing information for patients with Rapidly Progressive LAL deficiency and paediatric and adult patients with LAL deficiency is modified. In addition, editorial update is made in sections 4.8, 5.1, 5.2 and 6.6 following the new posology regimen. The Package Leaflet is updated accordingly."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.6. Opdivo - nivolumab - EMEA/H/C/003985/II/0105

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on final results from study CA209205 listed as a PAES in the Annex II; this is a Phase 2, open-label, multi-cohort, single-arm study of nivolumab in patients with classical Hodgkin's Lymphoma; The RMP version 20.3 has also been submitted."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

9.1.7. Vaxzevria – COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0021/G

AstraZeneca AB

Rapporteur: Sol Ruiz, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné

Scope: Quality variation

Action: For adoption

Request for Supplementary Information adopted on 24.06.2021 and 22.07.2021

The Committee discussed the issues identified in this application, relating to quality aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

9.1.8. Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0026

AstraZeneca AB

Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to include updated efficacy and safety information based on primary analysis from study D8110C00001 listed as a specific obligation in Annex II; this is a phase III randomised, double-blind, placebo-controlled, multicenter study in adults to determine the safety, efficacy and immunogenicity of Vaxzevria; the Package Leaflet and Annex II are updated accordingly. The updated RMP Version 3 Succession 2 has also been submitted."

Scope: Update on procedure

Action: For information

Request for Supplementary Information adopted on 22.07.2021

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

9.1.9. Imbruvica – imbrutinib – EMEA/H/C/003791

Janssen-Cilag International NV

Rapporteur: Filip Josephson, Co-Rapporteur: Sinan B. Sarac; PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Signal of sudden death / cardiac death with ibrutinib and concomitant ACE inhibitors

from a clinical trial; PRAC recommendation on a DHPC

Action: For discussion

The CHMP was updated on the procedure and informed that PRAC will further discuss Signal of sudden death / cardiac death with ibrutinib and concomitant ACE inhibitors from a clinical trial.

9.1.10. Staquis – crisaborole – EMEA/H/C/004863/P46/006

Pfizer Europe MA EEIG

Rapporteur: Andrea Laslop

Scope: Inclusion of data from early terminated study in 5.1 SmPC

Action: For adoption

The CHMP discussed the inclusion of data from early terminated study in 5.1 SmPC

9.1.11. Ocaliva - obeticholic acid - EMEA/H/C/004093/R/0027

Intercept Pharma International Limited

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Update on procedure, RSI

Action: For discussion

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.12. Ocaliva - obeticholic acid - EMEA/H/C/004093/II/0030

Intercept Pharma International Limited

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Update on procedure, RSI

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.13. Ondexxya– andexanet alfa - EMEA/H/C/004108/II/0003

Alexion Europe SAS,

Rapporteur: Jan Mueller-Berghaus,

Scope: Submission of the final report from Population PK and PK/PD Modelling Report (POR-PKPD-ADEX-321) listed as a category 2 study in the RMP/Specific Obligation 004 in Annex II

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.2.1. Vaxzevria – COVID-19 Vaccine (ChAdOx1-S [recombinant]) – EMEA/H/A-5(3)/1507

Astra Zeneca AB Referral

Rapporteur: Johann Lodewijk Hillege, Referral Co-Rapporteur: Sol Ruiz

Scope: Opinion

Action: For adoption

CHMP interim opinion adopted on 23.04.2021

Following the conclusion of a possible link between Vaxzevria and very rare cases of unusual blood clots with low blood platelets, to support decision making relating to vaccination campaigns at national level, the EC/Commission representative requested a further analysis and stratification of data under Article 5(3) of Regulation (EC) 726/2004, as well as, if possible providing a recommendation on the administration of the second dose of Vaxzevria on the basis of the available data.

On 23.04.2021, the CHMP adopted an interim opinion. The analyses showed that the benefits of vaccination increase with increasing age and increasing infections rates, however the data available did not allow to stratify the analyses by sex, nor to identify other possible risk factors. Conclusions from this analysis remain valid. Conclusions from this analysis remain valid.

The evidence did not allow EMA to identify particular risk factors that make TTS more likely. Although spontaneous reports when put in relation to the exposure have suggested that the risk may be higher in women and in younger adults, and lower after the second compared to the first dose, in view of the limitations of the way the data is collected, no strong conclusions could be drawn in terms of accurate predictive risk estimates.

The CHMP continues to be of the view that two separate doses of Vaxzevria should be administered 4 to 12 weeks apart, in line with the product information.

The Committee adopted a positive opinion by consensus.

The CHMP adopted the assessment report.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

September 2021 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the document.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Election of new CHMP chairperson

Harald Enzmann has served as Chair of the CHMP since 21 September 2018 and his first 3-year mandate will shortly come to an end.

The election of the new chairperson took place in accordance to the CHMP rules of procedure. The CHMP re-elected Harald Enzmann as new CHMP chair, for a three-year mandate, starting on 21 September 2021.

The CHMP and the Agency congratulated Harald Enzmann on his re-election and wished him all the best in his new role at the helm of the Committee.

14.1.2. Call for nomination for the election of new CHMP vice-chair

Bruno Sepodes has served as Vice-chair of the CHMP since 19 October 2018 and his first 3-year mandate will shortly come to an end.

The election of a new Vice-chairperson will take place at the end of the October 2021 CHMP plenary meeting as previously communicated to the Committee.

Candidates for the position of Vice-chair are invited to indicate their interest in standing for this position by circulating a letter of motivation and a brief résumé to the EMA by **Wednesday, 06 October 2021** EOB.

Action: For information

CHMP noted call for nomination for the election of new CHMP vice-chair.

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for September 2021

Action: For adoption

The CHMP adopted the EURD list.

14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at September 2021 PDCO

Action: For information

Report from the PDCO meeting held on 07-10 September 2021

Action: For information

The CHMP noted the report.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP September 2021 meeting to CHMP for adoption:

- 15 reports on products in scientific advice and protocol assistance
- 16 reports on products in pre-authorisation procedures
- 2 reports on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Scientific Advice Working Party (SAWP)

Chair: Anja Schiel

Report from the SAWP meeting held on 30 August - 02 September 2021. Table of conclusions

Action: For information

Scientific advice letters: Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.4. Cooperation within the EU regulatory network

14.4.1. Update on Pharmaceutical Strategy – Revision of general pharmaceutical acts

Presentation by DG SANTE ('20)

Action: For information

The CHMP noted the Update on Pharmaceutical Strategy – Revision of general pharmaceutical acts

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

14.8.1. Update of the Business Pipeline report for the human scientific committees

2021 initial marketing authorisation application submissions with eligibility request to central procedure

Action: For information

The CHMP noted the report.

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

The CHMP noted the update.

15.1.2. casirivimab, imdevimab – EMEA/H/C/005814

prevention and treatment of COVID-19

Scope: Rolling review list of questions

Action: For adoption

The CHMP adopted the list of questions.

15.1.3. regdanvimab – EMEA/H/C/005854

treatment of COVID-19

Scope: Rolling review list of questions

Action: For adoption

The CHMP adopted the list of questions.

15.1.4. Sputnik V, Gam-COVID-Vac, Component I - COVID-19 vaccine - EMEA/H/C/005861 Sputnik V, Gam-COVID-Vac, Component II - COVID-19 vaccine - EMEA/H/C/005875

prevention of COVID-19

Scope: Rolling review list of questions

Action: For adoption

The CHMP adopted the list of questions.

15.1.5. Scientific Advice Group (SAG) re-nominations

Re-nominations for SAG Vaccines, SAG Cardiovascular and SAG Infectious Disease

Action: For adoption

The CHMP adopted Re-nominations proposals for SAG Vaccines, SAG Cardiovascular and SAG Infectious Disease

15.1.6. Updated Guideline on registry-based studies

Presentation on the changes made to the Guideline on Registry-based studies following the public consultation.

Action: For adoption

The CHMP adopted Guideline on Registry-based studies following discussion at PROM meeting on 6th September 2021.

Lists of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 13-16 September 2021 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphy	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Ilko Getov	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Kirstine Moll Harboe	Alternate	Denmark	No interests declared	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantinos Markopoulos	Member	Greece	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Eleftheria Nikolaidi	Alternate	Greece	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Alternate	Iceland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting on	COVID-19 vaccines
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Bjorg Bolstad	Member	Norway	No restrictions applicable to this meeting	
Ingrid Wang	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No interests declared	
Nevenka Trsinar Brodt	Alternate	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Sabine Mayrhofer	Expert - via Webex*	Germany	No interests declared	
Irene Bachmann	Expert - via Webex*	Germany	No interests declared	
Nora Cascante Estepa	Expert - via Webex*	Germany	No interests declared	
Nina Hessvik	Expert - via WebEx*	Norway	No interests declared	
Fabrice Eroukhmanoff	Expert - via WebEx*	Norway	No restrictions applicable to this meeting	
Muriel Uzzan	Expert - via WebEx*	France	No interests declared	
Bruno Delafont	Expert - via WebEx*	France	No part in discussions, final deliberations and voting on	Vaxzevria – COVID-19 Vaccine (ChAdOx1-S [recombinant]) EMEA/H/A-5(3)/1507 II/0026 II/0021/G Nucala - mepolizumab X/0042 II/0035 II/0036/G II/0037
Vincent Gazin	Expert - via WebEx*	France	No interests declared	
Torbjorn Callréus	Expert - via WebEx*	Malta	No interests declared	
Michal Pirozynski	Expert - via WebEx*	Malta	No interests declared	
Stephanie Liane Cini	Expert - via WebEx*	Malta	No interests declared	
Paula Cardona Xuereb	Expert - via WebEx*	Malta	No interests declared	
Rowena Marie Agius	Expert - via WebEx*	Malta	No interests declared	
Alison Attard	Expert - via WebEx*	Malta	No interests declared	
Margaux Tiberi	Expert - via WebEx*	France	No interests declared	
Kairi Rooma	Expert - via WebEx*	Estonia	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Johanna Wernsperger	Expert - via WebEx*	Austria	No interests declared	
Walter Johannes Beiersdorf	Expert - via WebEx*	Austria	No restrictions applicable to this meeting	
Thomas Lang	Expert - via WebEx*	Austria	No interests declared	
Elisabeth Wischnitzki	Expert - via WebEx*	Austria	No interests declared	
Tjerk Feenstra	Expert - via WebEx*	Austria	No interests declared	
Philipp Janesch	Expert - via WebEx*	Austria	No interests declared	
Dace Peiseniece	Expert - via WebEx*	Latvia	No interests declared	
Ineta Popena	Expert - via WebEx*	Latvia	No interests declared	
Maria Grazia Evandri	Expert - via WebEx*	Italy	No interests declared	
Cristina Migali	Expert - via WebEx*	Italy	No interests declared	
Paolo Foggi	Expert - via WebEx*	Italy	No interests declared	
Adriana Ammassari	Expert - via WebEx*	Italy	No interests declared	
Antonella Isgrò	Expert - via WebEx*	Italy	No interests declared	
Sara Galluzzo	Expert - via WebEx*	Italy	No interests declared	
Simona Russo	Expert - via WebEx*	Italy	No restrictions applicable to this meeting	
Maria Victoria Tudanca Pacios	Expert - via Webex*	Spain	No restrictions applicable to this meeting	
Carolina Prieto Fernandez	Expert - via WebEx*	Spain	No interests declared	
Lucia Lopez-Anglada Fernandez	Expert - via WebEx*	Spain	No interests declared	
Macarena Gajardo	Expert - via WebEx*	Spain	No interests declared	
Alicia Pérez González	Expert - via WebEx*	Spain	No interests declared	
Maria Chamorro Somoza Diaz-Sarmiento	Expert - via WebEx*	Spain	No interests declared	
Ana Sagredo	Expert - via WebEx*	Spain	No interests declared	
Marcos Timón	Expert - via WebEx*	Spain	No interests declared	
Carmen Susana Rojo	Expert - via WebEx*	Spain	No interests declared	
Macarena Rodriguez Mendizabal	Expert - via WebEx*	Spain	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Johanna Kuhlmann-Gottke	Expert - via WebEx*	Germany	No restrictions applicable to this meeting	
Claudia Reichmann	Expert - via WebEx*	Germany	No interests declared	
Susanne Mueller-Egert	Expert - via WebEx*	Germany	No interests declared	
Hilke Zander	Expert - via WebEx*	Germany	No interests declared	
Bettina Kartmann	Expert - via WebEx*	Germany	No interests declared	
Martin Walter	Expert - via WebEx*	Austria	No interests declared	
George Aislaitner	Expert - via WebEx*	Germany	No interests declared	
Gabriele Schlosser-Weber	Expert - via WebEx*	Germany	No interests declared	
Christine Greiner	Expert - via WebEx*	Germany	No interests declared	
Olga Kholmanskikh	Expert - via WebEx*	Belgium	No interests declared	
Alexandru Mihail Simion	Expert - via WebEx*	Belgium	No interests declared	
Elina Asikanius	Expert - via WebEx*	Finland	No restrictions applicable to this meeting	
Tommi Nurminen	Expert - via WebEx*	Finland	No restrictions applicable to this meeting	
Hilke Johanna Van der Woude	Expert - via WebEx*	Netherlands	No interests declared	
Jorn Mulder	Expert - via WebEx*	Netherlands	No interests declared	
Wilhelm Johan de Waard	Expert - via WebEx*	Netherlands	No interests declared	
Marcel Maliepaard	Expert - via WebEx*	Netherlands	No interests declared	
Jacobus Romme	Expert - via WebEx*	Netherlands	No interests declared	
Emmely de Vries	Expert - via WebEx*	Netherlands	No interests declared	
Nienke Rodenhuis	Expert - via WebEx*	Netherlands	No interests declared	
Steven Teerenstra	Expert - via WebEx*	Netherlands	No interests declared	
Michel Kooijman	Expert - via WebEx*	Netherlands	No interests declared	
Eleonora Wijnans	Expert - via WebEx*	Netherlands	No interests declared	
Ingrid Schellens	Expert - via WebEx*	Netherlands	No interests declared	
Chantal van de Schootbrugge	Expert - via WebEx*	Netherlands	No interests declared	
Christel Loeb	Expert - via WebEx*	Netherlands	No interests declared	
Leon van Aerts	Expert - via WebEx*	Netherlands	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Andreas James Schaeffer Senders	Expert - via WebEx*	Denmark	No interests declared	
Anne-Marie Dalseg	Expert - via WebEx*	Denmark	No interests declared	
Mette Linnert Jensen	Expert - via WebEx*	Denmark	No interests declared	
Kristina Bech Jensen	Expert - via WebEx*	Denmark	No interests declared	
Deirdre Mannion	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Ebru Karakoc Madsen	Expert - via WebEx*	Denmark	No part in discussions, final deliberations and voting on	Vyepti - eptinezumab - EMEA/H/C/005287
Susanne Høpner Rasmussen	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Mette Tranholm	Expert - via WebEx*	Denmark	No interests declared	
Anne Hasle Buur	Expert - via WebEx*	Denmark	No interests declared	
Trine Jensen	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Jonas Bergh	Expert - via WebEx*	Sweden	No restrictions against giving the SAG report for Gavreto	
Anja Schiel	Expert - via WebEx*	Norway	No interests declared	
Andre Elferink	Expert - via WebEx*	Netherlands	No interests declared	
Elena Wolff-Holz	Expert - via WebEx*	Germany	No interests declared	
Mario Miguel Coelho da Silva Rosa	Expert - via WebEx*	Spain	No interests declared	
Elina Rönnemaa	Expert - via WebEx*	Sweden	No interests declared	
Ole Weis Bjerrum	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Caroline Auriche-Benichou	Expert - via WebEx*	France	No interests declared	
Adriana Andrić	Expert - via WebEx*	Croatia	No interests declared	
Elmer Schabel	Expert - via WebEx*	Germany	No interests declared	
Peter Mol	Expert - via WebEx*	Netherlands	No interests declared	
Paul Brown	Expert - via WebEx*	Denmark	No interests declared	
Martine Sabbe	Expert - via WebEx*	Belgium	No interests declared	
Greger Abrahamsen	Expert - via WebEx*	Norway	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Sven Rune Andersen	Expert - via WebEx*	Norway	No interests declared	
Paula Contreras Alarcón	Expert - via WebEx*	Spain	No restrictions applicable to this meeting	
Jaqueline Kerr	Expert - via WebEx*	Germany	No interests declared	
Edwige Haelterman Brenneisen	Expert - via WebEx*	Belgium	No interests declared	
Violette Dirix	Expert - via WebEx*	Belgium	No interests declared	
Martina Schuessler-Lenz	Expert - via WebEx*	Germany	No interests declared	
Eva A. Segovia	Expert - via WebEx*	Spain	No interests declared	
Mirjam Hinterleitner	Expert - via WebEx*	Austria	No interests declared	
Elisabeth Fuerst	Expert - via WebEx*	Austria	No interests declared	
Nikica Mirošević Skvrce	Expert - via WebEx*	Croatia	No interests declared	
Annika Folin	Expert - via WebEx*	Sweden	No interests declared	
Ieva Rutkovska	Expert - via WebEx*	Latvia	No interests declared	
Gorm Herlev Jørgensen	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Eva Malikova	Expert - via WebEx*	Slovakia	No interests declared	
Anna Kubandová	Expert - via WebEx*	Slovakia	No interests declared	
Jana Schweigertova	Expert - via WebEx*	Slovakia	No interests declared	
Peter Sisovsky	Expert - via WebEx*	Slovakia	No interests declared	
Kristin Skougaard	Expert - via WebEx*	Denmark	No interests declared	
Susana Vidic	Expert - via WebEx*	Slovenia	No restrictions applicable to this meeting	
Gaja Lesnicar Pucko	Expert - via WebEx*	Slovenia	No interests declared	
Jana Joseph	Expert - via WebEx*	Austria	No interests declared	
Elisabeth Johanne Rook	Expert - via WebEx*	Netherlands	No interests declared	
Karri Penttila	Expert - via WebEx*	Finland	No interests declared	
Victoria Starokozhko	Expert - via WebEx*	Netherlands	No restrictions applicable to this meeting	
Mair Powell	Expert - via WebEx*	Ireland	No interests declared	
Maura O'Donovan	Expert - via WebEx*	Ireland	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Violeta Stoyanova-Beninska	Expert - via WebEx*	Netherlands	No interests declared	
Darius Matusevicius	Expert - via WebEx*	Sweden	No restrictions applicable to this meeting	
Jens Reinhardt	Expert - via WebEx*	Germany	No interests declared	
Mohit Khera	Expert - via WebEx*	TGA, Australia	No interests declared	
Megan Hickie	Expert - via WebEx*	TGA, Australia	No interests declared	
Filip Kukulski	Expert - via WebEx*	Health Canada	No interests declared	
Tina Engraff	Expert - via WebEx*	EC	Confidentiality agreement	
Meeting run with the help of EMA staff				

*Experts were evaluated against the product(s) they have been invited to talk about

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

10 November 2021
EMA/635163/2021

Annex to 13-16 September 2021 CHMP Minutes

Pre-submission and post-authorisations issues

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for September 2021: **For adoption**	Adopted

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for September 2021: **For adoption**	Adopted

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

DECTOVA - zanamivir - EMEA/H/C/004102/S/0011 GlaxoSmithKline Trading Services Limited, Rapporteur: Bjorg Bolstad, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Daptomycin Hospira - daptomycin - EMEA/H/C/004310/R/0018 Pfizer Europe MA EEIG, Generic, Generic of Cubicin, Rapporteur: Kolbeinn Gudmundsson, PRAC Rapporteur: Pernille Harg	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members

	were in agreement with the CHMP Opinion.
Jylamvo - methotrexate - EMEA/H/C/003756/R/0015 Therakind (Europe) Limited, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Jan Neuhauser	Positive Opinion adopted by consensus together with the CHMP assessment report. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
LEDAGA - chlormethine - EMEA/H/C/002826/R/0030, Orphan Helsinn Birex Pharmaceuticals Limited, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Tiphaine Vaillant Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Olumiant - baricitinib - EMEA/H/C/004085/R/0025 Eli Lilly Nederland B.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Adam Przybylkowski Request for Supplementary Information adopted on 24.06.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Pregabalin Zentiva k.s. - pregabalin - EMEA/H/C/004277/R/0019 Zentiva k.s., Generic, Generic of Lyrica, Rapporteur: Alar Irs, PRAC Rapporteur: Liana Gross-Martirosyan	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Rolufta Ellipta - umeclidinium - EMEA/H/C/004654/R/0019 GlaxoSmithKline Trading Services Limited, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Ilaria Baldelli Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
SomaKit TOC - edotreotide - EMEA/H/C/004140/R/0019, Orphan	Positive Opinion adopted by consensus together with the CHMP assessment report and

Advanced Accelerator Applications, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Ronan Grimes Request for Supplementary Information adopted on 24.06.2021.	translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Suliqua - insulin glargine / lixisenatide - EMEA/H/C/004243/R/0022 sanofi-aventis groupe, Rapporteur: Kristina Dunder, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Tadalafil Lilly - tadalafil - EMEA/H/C/004666/R/0008 Eli Lilly Nederland B.V., Informed Consent of Cialis, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Talmanco - tadalafil - EMEA/H/C/004297/R/0011 Mylan S.A.S, Generic, Generic of Adcirca, Cialis, Rapporteur: Tomas Radimersky, PRAC Rapporteur: Maria del Pilar Rayon Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Truxima - rituximab - EMEA/H/C/004112/R/0047 Celltrion Healthcare Hungary Kft., Rapporteur: Sol Ruiz, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Anette Kirstine Stark	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

Yargesa - miglustat - EMEA/H/C/004016/R/0011 Piramal Critical Care B.V., Generic, Generic of Zavesca, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.

B.2.3. Renewals of Conditional Marketing Authorisations

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/R/0046 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/R/0006 Daiichi Sankyo Europe GmbH, Rapporteur: Sinan B. Sarac, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
NINLARO - ixazomib - EMEA/H/C/003844/R/0030, Orphan Takeda Pharma A/S, Rapporteur: Armando Genazzani, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
OCALIVA - obeticholic acid - EMEA/H/C/004093/R/0027, Orphan Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Liana Gross-Martirosyan Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable. See 9.1

on 16.09.2021.	
Polivy - polatuzumab vedotin - EMEA/H/C/004870/R/0008, Orphan Roche Registration GmbH, Rapporteur: Alexandre Moreau, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Annika Folin Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/R/0025 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Hans Christian Siersted	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
eTecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - EMEA/H/C/005102/R/0010, Orphan, ATMP Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Rune Kjeken, CHMP Coordinators: Jan Mueller-Berghaus and Ingrid Wang, PRAC Rapporteur: Menno van der Elst	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Signal detection	
PRAC recommendations on signals adopted at the PRAC meeting held on 30 August – 02 September 2021 PRAC:	

Signal of sudden death / cardiac death with ibrutinib and concomitant ACE inhibitors from a clinical trial Imbruvica – imbrutinib Rapporteur: Filip Josephson, Co-Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Nikica Mirošević Skvrce PRAC recommendation on a DHPC **Action:** For discussion	Noted See 9.1
Signal of progressive multifocal leukoencephalopathy Nordimet, Jylamvo – methotrexate Rapporteur: Bruno Sepodes, PRAC Rapporteur: Martin Huber PRAC recommendation on a variation **Action:** For adoption	Adopted
Signal of panniculitis Iclusig – ponatinib Rapporteur: Filip Josephson, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Annika Folin PRAC recommendation on a variation **Action:** For adoption	Adopted
PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its September 2021 meeting:	

EMEA/H/C/PSUSA/00001892/202012 (liraglutide) CAPS: **Saxenda** (EMEA/H/C/003780) (liraglutide), Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege **Victoza** (EMEA/H/C/001026) (liraglutide), Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, "01/01/2020 To: 31/12/2020"	The CHMP takes note of the PRAC recommendation concerning the maintenance of the terms of the Marketing Authorisation for the above mentioned medicinal product containing liraglutide for diabetes mellitus (Victoza). The current product information and any conditions to the marketing authorisation for the medicinal products containing the above referred active substance for diabetes mellitus remain unchanged. The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation for the above mentioned medicinal product containing liraglutide for weight management (Saxenda), concerning the following change: Update of section 4.8 of the SmPC to add the adverse reaction 'headache' with a frequency very common. The Package leaflet is to be updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00002511/202101 (pregabalin) CAPS: **Lyrica** (EMEA/H/C/000546) (pregabalin), Upjohn EESV, Rapporteur: Johann Lodewijk Hillege **Pregabalin Pfizer** (EMEA/H/C/003880) (pregabalin), Upjohn EESV, Rapporteur: Johann Lodewijk Hillege PRAC Rapporteur: Liana Gross-Martirosyan, "01/02/2020 To: 31/01/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s): Update of section 4.8 of the SmPC to Parkinsonism with frequency of "rare". The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00002948/202012 (ticagrelor) CAPS: **Brilique** (EMEA/H/C/001241) (ticagrelor), AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst,	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the

"01/01/2018 To: 31/12/2020"	above mentioned medicinal product(s), concerning the following change(s): Update of section 4.5 of the SmPC to add the interaction with rosuvastatin. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00003085/202012 (ustekinumab) CAPS: **Stelara** (EMEA/H/C/000958) (ustekinumab), Janssen-Cilag International NV, Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald, "01/01/2020 To: 31/12/2020"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation for the above-mentioned medicinal product, concerning the following changes: Update of section 4.4 of the SmPC to add a warning on Opportunistic infections. The Package leaflet is updated accordingly. Update of section 4.8 of the SmPC to add the adverse reaction bullous pemphigoid with a frequency very rare. The Package leaflet is updated accordingly. Update of section 4.6 of the SmPC to amend a warning on lactation. The Package leaflet is updated accordingly. Update of section 4.4 of the SmPC to add a warning on serious infusion related reactions. The Package leaflet is updated accordingly. Update of section 4.8 of the SmPC to amend a warning on serious infusion related reactions. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010075/202101 (dolutegravir, dolutegravir / abacavir / lamivudine, dolutegravir / lamivudine) CAPS: **Dovato** (EMEA/H/C/004909) (dolutegravir / lamivudine), ViiV Healthcare B.V., Rapporteur: Filip Josephson **Tivicay** (EMEA/H/C/002753) (dolutegravir), ViiV Healthcare B.V., Rapporteur: Filip Josephson **Triumeq** (EMEA/H/C/002754) (dolutegravir / abacavir / lamivudine), ViiV Healthcare B.V., Rapporteur: Filip Josephson, "17/01/2020 To: 16/01/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended together with the detailed explanation of the scientific grounds for the differences with the PRAC recommendation, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add adverse reaction "panic attack" with a frequency "uncommon". The Package leaflet is updated accordingly.

	The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010447/202101 (brivaracetam) CAPS: **Briviact** (EMEA/H/C/003898) (brivaracetam), UCB Pharma S.A., Rapporteur: Filip Josephson, PRAC Rapporteur: Adam Przybylkowski, "15/01/2020 To: 14/01/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended together with the detailed explanation of the scientific grounds for the differences with the PRAC recommendation, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.9 of the SmPC to add the adverse reactions reported in the context of overdose. The Package Leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010609/202101 (sarilumab) CAPS: **Kevzara** (EMEA/H/C/004254) (sarilumab), sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Eva A. Segovia, "12/01/2020 To: 12/01/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reactions leukopenia and diverticulitis and to amend the current warning on gastrointestinal perforation. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010664/202101 (budesonide (centrally authorised products only)) CAPS: **Jorveza** (EMEA/H/C/004655) (budesonide), Dr. Falk Pharma GmbH, Rapporteur: Martina Weise, PRAC Rapporteur: Zane Neikena, "08/07/2020 To: 07/01/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction angioedema with a frequency "uncommon". The Package leaflet is updated accordingly.

	The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010697/202101 (inotersen) CAPS: **Tegsedi** (EMEA/H/C/004782) (inotersen), Akcea Therapeutics Ireland Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Rhea Fitzgerald, "06/07/2020 To: 05/01/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.4. of the SmPC to amend a warning for patients undergoing liver transplantation. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010742/202101 (voretigene neparvovec) CAPS: **Luxturna** (EMEA/H/C/004451) (voretigene neparvovec), Novartis Europharm Limited, Rapporteur: Sol Ruiz, CHMP Coordinator: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Brigitte Keller-Stanislawski, "24/07/2020 To: 23/01/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction (chorio)retinal atrophy with a frequency not known. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

B.4. EPARs / WPARs

BXCL501 - dexmedetomidine - EMEA/H/C/005811 FGK Representative Service GmbH, indicated for acute treatment of agitation associated with schizophrenia and bipolar disorders, Known active substance (Article 8(3) of Directive No 2001/83/EC) **WPAR**	For information only. Comments can be sent to the PL in case necessary.
LIVMARLI (WD) - maralixibat - EMEA/H/C/005551, Orphan FGK Representative Service GmbH, Treatment of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment of Progressive Familial Intrahepatic	For information only. Comments can be sent to the PL in case necessary.

Cholestasis Type 2, New active substance (Article 8(3) of Directive No 2001/83/EC) **WPAR**	
Oportuzumab monatox DLRC Pharma Services - oportuzumab monatox - EMEA/H/C/005730 DLRC Pharma Services Ltd, Treatment and prevention of recurrence of carcinoma-in-situ (CIS) of the urinary bladder and prevention of recurrence of high grade Ta and/or T1 papillary tumours, New active substance (Article 8(3) of Directive No 2001/83/EC) **WPAR**	For information only. Comments can be sent to the PL in case necessary.
Teriparatide Cinnagen - teriparatide - EMEA/H/C/005543 CinnaGen Co, Unipessoal LDA, treatment of osteoporosis, Similar biological application (Article 10(4) of Directive No 2001/83/EC) **WPAR**	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/II/0021/G Baxalta Innovations GmbH, Rapporteur: Andrea Laslop Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 17.06.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/II/0022/G Baxalta Innovations GmbH, Rapporteur: Andrea Laslop Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Aimovig - erenumab - EMEA/H/C/004447/II/0017 Novartis Europharm Limited, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
AJOVY - fremanezumab -	Positive Opinion adopted by consensus on

EMEA/H/C/004833/II/0022 TEVA GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 09.09.2021.	09.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Alprolix - eftrenonacog alfa - EMEA/H/C/004142/II/0036/G, Orphan Swedish Orphan Biovitrum AB (publ), Rapporteur: Andrea Laslop Opinion adopted on 09.09.2021. Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus on 09.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Alymsys - bevacizumab - EMEA/H/C/005286/II/0004/G Mabxience Research SL, Rapporteur: Christian Gartner Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Aybintio - bevacizumab - EMEA/H/C/005106/II/0009 Samsung Bioepis NL B.V., Rapporteur: Andrea Laslop Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Benlysta - belimumab - EMEA/H/C/002015/II/0098 GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Ceprotin - human protein C - EMEA/H/C/000334/II/0121/G Takeda Manufacturing Austria AG, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 09.09.2021.	Request for supplementary information adopted with a specific timetable.
Ceprotin - human protein C - EMEA/H/C/000334/II/0122 Takeda Manufacturing Austria AG, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 09.09.2021.	Request for supplementary information adopted with a specific timetable.
Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) -	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

EMEA/H/C/000721/II/0112/G GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke Opinion adopted on 16.09.2021.	recommendation.
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0040/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 15.07.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0047/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0052/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0053/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 25.08.2021.	Positive Opinion adopted by consensus on 25.08.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0057 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 09.09.2021.	Positive Opinion adopted by consensus on 09.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0063/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Opinion adopted on 02.09.2021.	
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0065/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 09.09.2021.	Positive Opinion adopted by consensus on 09.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0066 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 13.09.2021.	Positive Opinion adopted by consensus on 13.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Cyramza - ramucirumab - EMEA/H/C/002829/II/0041 Eli Lilly Nederland B.V., Rapporteur: Paula Boudewina van Hennik Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 24.06.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Drovelis - drospirenone / estetrol - EMEA/H/C/005336/II/0001/G Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.), Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Enbrel - etanercept - EMEA/H/C/000262/II/0243/G Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Epidyolex - cannabidiol - EMEA/H/C/004675/II/0014/G, Orphan GW Pharma (International) B.V., Rapporteur: Kirstine Moll Harboe Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
EVRA - ethinylestradiol / norelgestromin -	Positive Opinion adopted by consensus on

EMEA/H/C/000410/II/0048/G Gedeon Richter Plc., Rapporteur: Paula Boudewina van Hennik Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 20.05.2021, 14.01.2021.	02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Eylea - aflibercept - EMEA/H/C/002392/II/0071/G Bayer AG, Rapporteur: Alexandre Moreau Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 15.07.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Eylea - aflibercept - EMEA/H/C/002392/II/0074 Bayer AG, Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Flebogamma DIF - human normal immunoglobulin - EMEA/H/C/000781/II/0067 Instituto Grifols, S.A., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Gardasil 9 - human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) - EMEA/H/C/003852/II/0046 MSD Vaccins, Rapporteur: Kristina Dunder Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Hemlibra - emicizumab - EMEA/H/C/004406/II/0023/G Roche Registration GmbH, Rapporteur: Alexandre Moreau Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Herceptin - trastuzumab - EMEA/H/C/000278/II/0173 Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 09.09.2021.	Request for supplementary information adopted with a specific timetable.

Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0128 CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 17.06.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Iclusig - ponatinib - EMEA/H/C/002695/II/0060/G, Orphan Incyte Biosciences Distribution B.V., Rapporteur: Filip Josephson Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Imfinzi - durvalumab - EMEA/H/C/004771/II/0032 AstraZeneca AB, Rapporteur: Sinan B. Sarac Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
LIBTAYO - cemiplimab - EMEA/H/C/004844/II/0020/G Regeneron Ireland Designated Activity Company (DAC), Rapporteur: Sinan B. Sarac Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Lydisilka - drospirenone / estetrol - EMEA/H/C/005382/II/0001/G Estetra SRL, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Lysodren - mitotane - EMEA/H/C/000521/II/0024 HRA Pharma Rare Diseases, Rapporteur: Blanca Garcia-Ochoa Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
MabThera - rituximab - EMEA/H/C/000165/II/0186 Roche Registration GmbH, Rapporteur: Sinan B. Sarac Request for Supplementary Information adopted on 09.09.2021.	Request for supplementary information adopted with a specific timetable.
Menveo - Meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/001095/II/0103	Request for supplementary information adopted with a specific timetable.

GSK Vaccines S.r.l, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 02.09.2021.	
Mepsevii - vestronidase alfa - EMEA/H/C/004438/II/0024, Orphan Ultragenyx Germany GmbH, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Metalyse - tenecteplase - EMEA/H/C/000306/II/0064/G Boehringer Ingelheim International GmbH, Rapporteur: Martina Weise Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Miglustat Gen.Orph - miglustat - EMEA/H/C/004366/II/0018 Gen.Orph, Generic, Generic of Zavesca, Rapporteur: Daniela Philadelphy Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Nepexto - etanercept - EMEA/H/C/004711/II/0010/G Mylan IRE Healthcare Limited, Rapporteur: Martina Weise Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Nepexto - etanercept - EMEA/H/C/004711/II/0011 Mylan IRE Healthcare Limited, Rapporteur: Martina Weise Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Nimenrix - Meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/002226/II/0108/G Pfizer Europe MA EEIG, Rapporteur: Bjorg Bolstad Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 17.06.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Ogivri - trastuzumab - EMEA/H/C/004916/II/0028	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP

Viatris Limited, Rapporteur: Karin Janssen van Doorn Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 20.05.2021.	Members were in agreement with the CHMP recommendation.
Ogivri - trastuzumab - EMEA/H/C/004916/II/0033 Viatris Limited, Rapporteur: Karin Janssen van Doorn Opinion adopted on 09.09.2021.	Positive Opinion adopted by consensus on 09.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Olanzapine Apotex - olanzapine - EMEA/H/C/001178/II/0045 Apotex Europe BV, Generic, Generic of Zyprexa, Rapporteur: John Joseph Borg Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Olanzapine Apotex - olanzapine - EMEA/H/C/001178/II/0046/G Apotex Europe BV, Generic, Generic of Zyprexa, Rapporteur: John Joseph Borg Opinion adopted on 09.09.2021.	Positive Opinion adopted by consensus on 09.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
OPDIVO - nivolumab - EMEA/H/C/003985/II/0106/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Blanca Garcia-Ochoa Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Oyavas - bevacizumab - EMEA/H/C/005556/II/0003/G STADA Arzneimittel AG, Duplicate, Duplicate of Alymsys, Rapporteur: Christian Gartner Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Palforzia - defatted powder of arachis hypogaea l., semen (peanuts) - EMEA/H/C/004917/II/0004/G Aimmune Therapeutics Ireland Limited, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Palynziq - pegvaliase - EMEA/H/C/004744/II/0019, Orphan BioMarin International Limited, Rapporteur: Johann Lodewijk Hillege	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 17.06.2021.	
Pemetrexed Sandoz - pemetrexed - EMEA/H/C/004011/II/0011/G Sandoz GmbH, Generic, Generic of Alimta, Rapporteur: Bjorg Bolstad Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 24.06.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Perjeta - pertuzumab - EMEA/H/C/002547/II/0060/G Roche Registration GmbH, Rapporteur: Sinan B. Sarac Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Remsima - infliximab - EMEA/H/C/002576/II/0101/G Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola Request for Supplementary Information adopted on 02.09.2021, 03.06.2021.	Request for supplementary information adopted with a specific timetable.
Replagal - agalsidase alfa - EMEA/H/C/000369/II/0112/G Shire Human Genetic Therapies AB, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 09.09.2021. Request for Supplementary Information adopted on 10.06.2021.	Positive Opinion adopted by consensus on 09.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Resolor - prucalopride - EMEA/H/C/001012/II/0052 Takeda Pharmaceuticals International AG, Rapporteur: Kristina Dunder Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 20.05.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
RoActemra - tocilizumab - EMEA/H/C/000955/II/0102/G Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
SCENESSE - afamelanotide - EMEA/H/C/002548/II/0037, Orphan	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP

Clinuvel Europe Limited, Rapporteur: Janet Koenig Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 28.05.2021.	Members were in agreement with the CHMP recommendation.
Spectrila - asparaginase - EMEA/H/C/002661/II/0025 medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Andrea Laslop Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0024/G Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0029/G Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 23.08.2021.	Positive Opinion adopted by consensus on 23.08.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0085/G MCM Vaccine B.V., Rapporteur: Christophe Focke Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0021/G AstraZeneca AB, Rapporteur: Sol Ruiz Request for Supplementary Information adopted on 16.09.2021, 22.07.2021, 24.06.2021.	Request for supplementary information adopted with a specific timetable. See 9.1
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0030/G	Request for supplementary information adopted with a specific timetable.

AstraZeneca AB, Rapporteur: Sol Ruiz Request for Supplementary Information adopted on 02.09.2021.	
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0035/G AstraZeneca AB, Rapporteur: Sol Ruiz Request for Supplementary Information adopted on 10.09.2021, 19.08.2021.	Request for supplementary information adopted with a specific timetable.
Vazkepa - icosapent ethyl - EMEA/H/C/005398/II/0003 Amarin Pharmaceuticals Ireland Limited, Rapporteur: Martina Weise Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
VEYVONDI - vonicog alfa - EMEA/H/C/004454/II/0019/G Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Xofigo - radium-223 - EMEA/H/C/002653/II/0041 Bayer AG, Rapporteur: Janet Koenig Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 10.06.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Xofigo - radium-223 - EMEA/H/C/002653/II/0042/G Bayer AG, Rapporteur: Janet Koenig Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 10.06.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Zavicefta - ceftazidime / avibactam - EMEA/H/C/004027/II/0027/G Pfizer Ireland Pharmaceuticals, Rapporteur: Ingrid Wang Request for Supplementary Information adopted on 09.09.2021.	Request for supplementary information adopted with a specific timetable.
Ziextenzo - pegfilgrastim - EMEA/H/C/004802/II/0014 Sandoz GmbH, Rapporteur: Andrea Laslop	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 15.07.2021.	recommendation.
Zubsolv - buprenorphine / naloxone - EMEA/H/C/004407/II/0015 Accord Healthcare S.L.U., Rapporteur: Peter Kiely Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 08.07.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2118/G **Blitzima-EMEA/H/C/004723/WS2118/0044/G** **Truxima-EMEA/H/C/004112/WS2118/0048/G** Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
WS2120 **Nuwiq-EMEA/H/C/002813/WS2120/0045** **Vihuma-EMEA/H/C/004459/WS2120/0027** Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0089, Orphan Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik, "Submission of long-term follow-up data for clinical trial Echelon-2 (SGN035-014): A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphoma. The study is submitted to fulfil the post-approval-measure MEA 015.1. Section 5.1 of the SmPC has been updated to reflect this follow-up." Opinion adopted on 16.09.2021. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

on 24.06.2021.	
Adempas - riociguat - EMEA/H/C/002737/II/0032/G, Orphan Bayer AG, Rapporteur: Johann Lodewijk Hillege, "Group of variations: Type II C.I.4. update to SmPC section 4.3 and section 4.5 to contraindicate coadministration of riociguat (adempas) with other sGC stimulators. Type II C.I.4. update to SmPC section 4.5 to rectify the Cmax value related to concomitant use with HAART treatment. The package leaflet is updated accordingly. In addition, the MAH takes to opportunity to implement editorial changes and updates to QRD Template version 10.2." Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Afinitor - everolimus - EMEA/H/C/001038/II/0073 Novartis Europharm Limited, Rapporteur: Janet Koenig, "Update of the SmPC section 5.1 based on the results of the analysis of final progression free and overall survival (OS) for study CRAD001T2302." Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Alecensa - alectinib - EMEA/H/C/004164/II/0034 Roche Registration GmbH, Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC in order to add haemolytic anaemia to the list of adverse drug reactions (ADRs) with frequency common, based on a report of cumulative safety data (DSR1104210); the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2. Moreover, the MAH took the opportunity to introduce editorial changes in the Greek, Swedish, Dutch, Danish, Latvian, Croatian, Portuguese and Czech PI." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 08.07.2021, 20.05.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Brilique - ticagrelor - EMEA/H/C/001241/II/0050 AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, "Update of the SmPC in order to add central sleep apnoea including Cheyne-Stokes respiration as a new warning in section 4.4.,	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

following collection of post-marketing data; the Package Leaflet is updated accordingly." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 20.05.2021.	
Calquence - acalabrutinib - EMEA/H/C/005299/II/0004 AstraZeneca AB, Rapporteur: Filip Josephson, "Submission of the final report of the nonclinical study 20266648 (5336BV) (Acalabrutinib: Neutral Red Uptake Phototoxicity Assay in BALB/c 3T3 Mouse Fibroblasts), in response to the CHMP recommendation to submit results from a modified 3T3 NRU phototoxicity study with adjusted wavelengths. This variation does not propose amendments to the PI." Request for Supplementary Information adopted on 16.09.2021, 20.05.2021.	Request for supplementary information adopted with a specific timetable.
CellCept - mycophenolate mofetil - EMEA/H/C/000082/II/0165/G Roche Registration GmbH, Rapporteur: Kirstine Moll Harboe, "C.I.4 (Type II) - Update of section 5.1 of the SmPC with recent findings from a clinical Pharmacology position paper on Mycophenolate mechanism of Action. - C.I.4 (Type II) - Update of section 5.2 of the SmPC to add new information to the distribution and elimination subsections based on a Clinical Pharmacology Position Paper. - C.I.4 (Type II) - Update of section 5.2 of the SmPC to amend the existing information on patients taking oral contraceptives based on study Roche Report N-181041/ BP 15543. Section 4.5 of the SmPC has been updated accordingly. - C.I.Z (Type IB) - Update of section 2 and section 6 of the Package Leaflet to implement recommendations from NCA (Ireland) and EMA. The Package Leaflet is updated accordingly. In addition, the Marketing Authorisation Holder (MAH) has taken the opportunity to implement minor editorial changes to the SmPC and Package Leaflet. Furthermore, the PI is being brought in line with the latest QRD template version 10.2. " Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Cimzia - certolizumab pegol - EMEA/H/C/001037/II/0098	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP

UCB Pharma S.A., Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to update the safety information on active axial spondyloarthritis based on study AS0007 (C-VIEW); this is a multicenter, open-label study to assess the effects of certolizumab pegol on the reduction of anterior uveitis flares in axial spondyloarthritis subjects with a history of anterior uveitis. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 28.05.2021.	Members were in agreement with the CHMP recommendation.
Dapivirine Vaginal Ring 25 mg - dapivirine - EMEA/H/W/002168/II/0007 International Partnership for Microbicides Belgium AISBL, Rapporteur: Paula Boudewina van Hennik, "Submission of the final report for study report no. 15760.01, conducted to evaluate the antiviral activity of dapivirine on hepatitis E virus (HEV) in vitro. In addition, the SOH took the opportunity to submit data on: antiviral activity of Dapivirine against influenza A and B viruses; the effects of a vaginal film formulation of dapivirine on various species of Lactobacilli present in the vagina; the antitumor activity of dapivirine in glioblastoma cells. With this submission, the post authorisation measure REC 001 is addressed." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 28.05.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Darzalex - daratumumab - EMEA/H/C/004077/II/0050, Orphan Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, "C.I.4 Update of section 4.8 of the SmPC in order to add hypogammaglobulinemia to the list of adverse drug reactions (ADRs) with frequency common, based on new information and previously reviewed pooled safety data from Part 2 of Phase 3 clinical study 54767414MMY3006 comparing daratumumab versus observation as maintenance in patients with newly diagnosed Multiple Myeloma who are post-ASCT transplant. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 02.09.2021.	
Darzalex - daratumumab - EMEA/H/C/004077/II/0051/G, Orphan Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, "C.I.4 Update of section 5.1 of the SmPC in order to update PFS and OS data based on interim results from study MMY3006 (CCO 27/8/2020); this is a Phase 3, randomized, open-label, parallel-group, active-control, multicenter study of daratumumab combined with VTd for NDMM patients eligible for ASCT. This fulfils a post-approval commitment of procedure EMEA/H/C/004077//II/0030 to provide updated Part 1 PFS and OS data, with censoring the patients randomized to daratumumab in Part 2 of this study. C.I.4 Update of section 5.1 of the SmPC of DARZALEX SC formulation to provide the mature OS data based on final results from study MMY3012 (CCO 04/11/2020); this is a Phase 3, multicenter, randomized, open-label, active-controlled study to demonstrate that the efficacy and PK for daratumumab SC are not inferior to those for daratumumab IV in subjects with RRMM submitted for the approval of the SC formulation in procedure EMEA/H/C/004077/II/0032" Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Darzalex - daratumumab - EMEA/H/C/004077/II/0053, Orphan Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, "C.I.4 Update of section 5.1 of the SmPC in order to update PFS and OS (CCO 19/2/2021) data based on interim results from study MMY3008; This is a Phase 3, randomized, open-label, active controlled, parallel-group, multicenter study in adults with newly diagnosed MM not eligible for ASCT comparing DRd vs Rd. The Marketing authorisation holder (MAH) took the opportunity to make minor formatting and linguistic changes in the PI." Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0005/G	Request for supplementary information adopted with a specific timetable.

Daiichi Sankyo Europe GmbH, Rapporteur: Sinan B. Sarac, "Submission of two final study reports recommended at the time of the initial MA: I. study investigating in vitro pharmacological action of MAAA-11181d on receptors, channels, transporters and enzymes (Study No.: TW04-0008917); II. pharmacodynamic study to investigate the in-vitro binding profile of MAAA-1181a in Human, Monkey, and Rat Liver Microsomes (Study No.: AE-8630-G). Submission of the final report of the in vitro CYP3A4, CYP1A2 and CYP2B6 induction study in primary human hepatocytes (Study No.: TCRM-DMPK-2020-19)." Request for Supplementary Information adopted on 16.09.2021.	
Entyvio - vedolizumab - EMEA/H/C/002782/II/0059/G Takeda Pharma A/S, Rapporteur: Armando Genazzani, "C.I.4 Update of section 4.6 of the SmPC in order to implement information on lactation based on study Vedolizumab-4001 (An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically). The study aimed to determine the PK parameters of vedolizumab in breast milk and to estimate mean daily infant dosage over the dosing interval through breast milk, and percentage of maternal dose consumed in breast milk by the infants. C.I.4 Update of section 5.2 of the SmPC in order to adjust the values for clearance and serum half-life of vedolizumab IV and SC in subjects with ulcerative colitis and Crohn's disease. The updated pop PK dataset consists of pooled data across 4 phase 3 studies (C13006, C13007, MLN0002SC-3027, MLN0002SC-3031) and 1 open-label extension study (MLN0002SC-3030). In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, to correct minor typographical errors and to bring the PI in line with the latest QRD template version 10.2 rev. 1."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 02.09.2021, 10.06.2021.	
Erleada - apalutamide - EMEA/H/C/004452/II/0015 Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, "Update of section 5.1 of the SmPC in order to update the efficacy and safety information based on final results from study 56021927PCR3002 (TITAN) listed as Letter of Recommendations (11 December 2019, EMEA/H/C/004452/II/0001); this is a double-blind, placebo-controlled, multinational, multicenter Phase 3 study in metastatic castration-sensitive prostate cancer (mCSPC) patients." Request for Supplementary Information adopted on 02.09.2021, 08.07.2021.	Request for supplementary information adopted with a specific timetable.
Erleada - apalutamide - EMEA/H/C/004452/II/0016 Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, "Update of section 4.8 of the SmPC in order to add Stevens-Johnson Syndrome (SJS) to the list of adverse drug reactions (ADRs) with frequency not known. Cases of SJS were observed in post-marketing data. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Eylea - aflibercept - EMEA/H/C/002392/II/0073 Bayer AG, Rapporteur: Alexandre Moreau, "C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority. PFS design change." Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Fintepla - fenfluramine - EMEA/H/C/003933/II/0002, Orphan Zogenix ROI Limited, Rapporteur: Kirstine Moll Harboe, "Update of section 4.2 of the SmPC to reduce the potential for confusion of the posology instructions by removing the dosing tables. This change is based on the inconsistencies found between the hand calculations and the values in the dosing tables	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

following unsolicited comments from doctors and a recommendation from Zogenix Advisory Board." Opinion adopted on 16.09.2021.	
Giotrif - afatinib - EMEA/H/C/002280/II/0039/G Boehringer Ingelheim International GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to update the description of paediatric information based on results of paediatric study 1200.120. This is in compliance with a completed paediatric investigation plan which do not support a paediatric indication. The Package Leaflet is updated accordingly. The ATC code is also updated. In addition, the MAH took the opportunity to make some minor administrative changes to the labelling and package leaflet." Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Imfinzi - durvalumab - EMEA/H/C/004771/II/0030/G AstraZeneca AB, Rapporteur: Sinan B. Sarac, "Update of sections 4.2. and 4.4 the SmPC in order to change posology recommendations for management of immune-mediated adverse reactions and amend an existing warning on Immune-mediated type 1 diabetes mellitus to include diabetic ketoacidosis; these changes are based on case studies reports, updated guidelines. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make some minor corrections to section 4.8 of the SmPC." Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 24.06.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Jardiance - empagliflozin - EMEA/H/C/002677/II/0057 Boehringer Ingelheim International GmbH, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.2 and 4.4 of the SmPC to lower the renal threshold for initiation and use of empagliflozin depending on eGFR, and of the section 5.1 wording about endpoints with reference to EMPA-REG OUTCOME study. The PL is updated accordingly." Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation. See 9.1

Request for Supplementary Information adopted on 24.06.2021, 25.03.2021.	
Jinarc - tolvaptan - EMEA/H/C/002788/II/0033/G Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Armando Genazzani, "Update of section 4.5 of the SmPC in order to update the safety information based on final results from study 156-201-00233 and 156-201-00234; the Package Leaflet is updated accordingly." Opinion adopted on 09.09.2021. Request for Supplementary Information adopted on 10.06.2021.	Positive Opinion adopted by consensus on 09.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Jyseleca - filgotinib - EMEA/H/C/005113/II/0008 Gilead Sciences Ireland UC, Rapporteur: Kristina Dunder, "C.I.4 - Update of section 4.8 of the SmPC in order to add Lymphopenia to the list of adverse drug reactions (ADRs) with frequency common and update the information on serum phosphate and the experience from the long-term extension studies based on interim results from study GS-US-417-0304 (FINCH 4); this is a Multicenter, Double-Blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis; the Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 09.09.2021.	Request for supplementary information adopted with a specific timetable.
Kanuma - sebelipase alfa - EMEA/H/C/004004/II/0032, Orphan Alexion Europe SAS, Rapporteur: Karin Janssen van Doorn, "Update of section 4.2 of the SmPC in order to introduce a new posology regimen (higher starting dose of 3 mg/kg once weekly) based on cumulative data from clinical studies and real-world clinical practice for patients with Rapidly Progressive LAL deficiency presenting within the first six months of life. Consequently, the dosing information for patients with Rapidly Progressive LAL deficiency and paediatric and adult patients with LAL deficiency is modified. In addition, editorial update is made in sections 4.8, 5.1, 5.2 and 6.6 following the new posology regimen. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable. See 9.1

on 16.09.2021.	
Kineret - anakinra - EMEA/H/C/000363/II/0080/G Swedish Orphan Biovitrum AB (publ), Rapporteur: Kirstine Moll Harboe, "Update of section 4.4 of the SmPC in order to include new safety information about Macrophage activation syndrome (MAS) in the 'serious infections' subsection and to update the 'pulmonary events' subsections with new safety information. Update of section 4.8 of the SmPC to amend the summary of safety profile, the 'serious infections', the 'neutropenia', 'allergic reactions', 'immunogenicity', 'paediatric population' and the 'injection site reactions' subsections with new safety information. Update of section 5.1 of the SmPC to update the clinical efficacy and safety information in Still's disease. The updates proposed are based on the results from study Sobi.ANAKIN-301 (evaluated in procedure no. EMA/H/C/000363/P46/031) and Sobi.ANAKIN-302 (evaluated in procedure no. EMEA/H/C/000363/II/0073). Sobi.ANAKIN-301 was a randomised, double-blind, placebo-controlled, multicenter, phase 3 study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of anakinra as compared to placebo in newly diagnosed Still's disease patients (including systemic juvenile idiopathic arthritis [SJIA] and adult-onset Still's disease [AOSD]). Sobi.ANAKIN-302 was a non-interventional, post-authorisation safety study to evaluate long-term safety of anakinra in patients with SJIA. In addition, the MAH took the opportunity to correct in SmPC section 4.8 the MedDRA System Organ Class (SOC) for the adverse reaction 'Injection Site Reaction' and changed the SOC from 'Skin and subcutaneous tissue disorder' to 'General disorders and administration site conditions'; and to align the product information with QRD template 10.2 rev.1. Further, minor editorial corrections were introduced in the SmPC. Those changes are accepted by CHMP." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

on 06.05.2021.	
Lynparza - olaparib - EMEA/H/C/003726/II/0047 AstraZeneca AB, Rapporteur: Alexandre Moreau, "Update of sections 4.8 and 5.1 of the SmPC in order to update safety and efficacy information based on the final analysis of overall survival and safety update from study POLO, a Phase III, randomised, double-blind, placebo-controlled, multicentre study in gBRCAm patients with metastatic pancreatic adenocarcinoma whose disease had not progressed after receiving first-line platinum-based chemotherapy." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 28.05.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Lynparza - olaparib - EMEA/H/C/003726/II/0048 AstraZeneca AB, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ilaria Baldelli, "Update of section 5.1 of the olaparib tablet SmPC based on results from study D0816C00020 (OPINION) listed as a PAES in the Annex II; this is a Phase IIIb single arm, multicentre study, investigating olaparib as a maintenance treatment in patients with platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer following 2 or more lines of platinum based chemotherapy and who did not have a known deleterious or suspected deleterious gBRCA mutation; the Annex II is updated accordingly. The RMP version 22.1 has also been submitted." Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Mavenclad - cladribine - EMEA/H/C/004230/II/0016 Merck Europe B.V., Rapporteur: Kirstine Moll Harboe, "Update of section 4.8 of the SmPC in order to add hypersensitivity to the list of adverse drug reactions (ADRs) with frequency "common" based on a review of cumulative clinical and post-marketing data. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 02.09.2021, 20.05.2021, 14.01.2021.	Request for supplementary information adopted with a specific timetable.
MenQuadfi - Meningococcal group A, C, W135 and Y conjugate vaccine -	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP

EMEA/H/C/005084/II/0006 Sanofi Pasteur, Rapporteur: Andrea Laslop, "Update of section 5.1 of the SmPC based on final results from study MET62, listed in the Annex II (category 1 in the RMP); this is a study to investigate immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated 3 years earlier as toddlers (ANX 001). In addition, the MAH took the opportunity to include minor editorial changes in Annex II of the product information." Opinion adopted on 02.09.2021.	Members were in agreement with the CHMP recommendation.
Myalepta - metreleptin - EMEA/H/C/004218/II/0020/G, Orphan Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn, "2 x C.I.13: Submission of 2 final non-clinical study reports assessing the binding of metreleptin to proteins in serum and characterising the tissue distribution of metreleptin. These are two agreed PAM-REC studies: a comparative in-vitro study of the binding of 125I-labelled leptin and 125I-labelled metreleptin in human serum at the therapeutic concentration range, and an in-vivo study comparing the tissue distribution of 125I-labelled metreleptin and 125I-labelled leptin in mice." Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Natpar - parathyroid hormone - EMEA/H/C/003861/II/0030/G, Orphan Shire Pharmaceuticals Ireland Limited, Rapporteur: Karin Janssen van Doorn, "Submission of the clinical study reports of the following two studies: • SHP634-402 - A Phase 4, Open-Label, Single-Center Clinical Study of Extended use of rhPTH(1-84) in Hypoparathyroidism • SHP634-404 - An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects with Hypoparathyroidism. " Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Nerlynx - neratinib - EMEA/H/C/004030/II/0021 Pierre Fabre Medicament, Rapporteur: Bruno Sepodes, "Update of sections 5.3 and 6.6 of the SmPC based on an updated environmental risk	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

assessment including ERA studies" Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 20.05.2021.	
OCALIVA - obeticholic acid - EMEA/H/C/004093/II/0029, Orphan Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.2, 4.5 and 5.2 of the SmPC in order to clarify information on posology recommendations in renally impaired patients and add information on pharmacokinetic properties following the results from study 474-120 (a Phase I, Open-Label Study to Investigate the Effect of Renal Impairment on the Single-Dose Pharmacokinetics of Obeticholic Acid). Editorial changes have also been made to section 4.5." Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
OCALIVA - obeticholic acid - EMEA/H/C/004093/II/0030, Orphan Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa, "Update of section 4.3 of the SmPC in order to include contraindication in patients with decompensated cirrhosis (e.g., Child-Pugh Class B or C) or a prior decompensation event based on the MAH's conclusion that it will not be feasible to establish the safety and efficacy of Ocaliva in these patients from either of the ongoing studies 747-302 and 747-401 listed as Specific Obligations in Annex II. Consequently, dosing instructions for patients with CP-B and CP-C cirrhosis are no longer applicable and section 4.2 has been updated accordingly. In addition, section 4.4 of the SmPC to include a new warning on monitoring and management of patients for possible progression of PBC and other hepatic adverse reactions. The MAH also took the opportunity to remove the outdated term, "primary biliary cirrhosis", from section 4.1 and to make editorial changes to sections 4.8, 4.9, 5.1 and Annex IIE to improve clarity and correct typographical errors. The Package Leaflet is updated accordingly. Furthermore, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2"	Request for supplementary information adopted with a specific timetable. See 9.1

Request for Supplementary Information adopted on 16.09.2021.	
Omnitrope - somatropin - EMEA/H/C/000607/II/0071 Sandoz GmbH, Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to add 'headache' and 'hypothyroidism' to the list of adverse drug reactions (ADRs) with frequency not known based on final results from study EP00-501 (PATRO children), which were assessed in accordance with Article 46 of Regulation (EC) No1901/2006; this is an international, non-interventional, non-controlled, longitudinal, open and multicenter study, designed to record the safety and effectiveness data of paediatric patients treated with Omnitrope in various indications within routine clinical practice; the Package Leaflet is updated accordingly. Section 5.1 of the SmPC was updated to include the study results of study EP00-501. In addition, the MAH took the opportunity to align the summary of the safety profile and the tabulated list of ADRs, to introduce statements in the PI as per the Excipients guideline and to bring the PI in line with the latest QRD template version 10.2." Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0003 Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus, "Submission of the final report from Population PK and PK/PD Modelling Report (POR-PKPD-ADEX-321) listed as a category 2 study in the RMP/Specific Obligation 004 in Annex II." Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 20.05.2021, 25.02.2021, 28.05.2020, 12.12.2019.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation. See 9.1
Pergoveris - follitropin alfa / lutropin alfa - EMEA/H/C/000714/II/0075 Merck Europe B.V., Rapporteur: Kirstine Moll Harboe, "Update of sections 4.1, 4.2, 4.4, 5.1, 5.2 and 6.6 of the SmPC in order to revise the definition of severe LH and FSH deficiency and to clarify the treatment target and the pharmacokinetic and pharmacodynamic properties of the two gonatropins included in the medicinal product, as well as disposal	Request for supplementary information adopted with a specific timetable.

precautions, based on current medical guidelines, clinical practice and literature; the Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1 and to align with the guideline on the Excipients in the labelling and package leaflet of the medicinal products for human use." Request for Supplementary Information adopted on 02.09.2021.	
Prialt - ziconotide - EMEA/H/C/000551/II/0068 Riemser Pharma GmbH, Rapporteur: Christophe Focke, "Update of section 4.2 of the SmPC to introduce a new posology regimen. The Package Leaflet to be updated accordingly. In addition, the MAH took the opportunity to update QRD template to v.10.2 Rev.1 and implement editorial changes in SmPC, PL and Labelling." Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Remicade - infliximab - EMEA/H/C/000240/II/0227 Janssen Biologics B.V., Rapporteur: Kristina Dunder, "Update of the breast-feeding information in section 4.6 of the SmPC to reflect the latest findings from literature regarding excretion of infliximab in human milk and the lack of impact on the development of breastfed infants. The local representative section in the Package leaflet has also been updated." Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 18.03.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Saxenda - liraglutide - EMEA/H/C/003780/II/0030 Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, "Update in the SmPC section 5.1 based on results from phase 3a clinical trial NN8022-4179, listed as part of PIP, to evaluate efficacy/safety of liraglutide in obese children with Prader-Willi Syndrome from 6 up to 18 years." Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Spinraza - nusinersen - EMEA/H/C/004312/II/0023, Orphan	Request for supplementary information adopted with a specific timetable.

Biogen Netherlands B.V., Rapporteur: Bruno Sepodes, "Update of section 5.1 of the SmPC to include information on real-world use of nusinersen in adults." Request for Supplementary Information adopted on 16.09.2021.	
Synflorix - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/000973/II/0160 GlaxoSmithkline Biologicals SA, Rapporteur: Kristina Dunder, "Update of section 5.1 Pharmacodynamic properties of the SmPC following submission of procedure EMEA/H/C/000973/P46/070 to include results of the study 10PN-PD-DIT-082, a phase III, controlled, partially-blind study evaluating the interchangeability of Synflorix and 13-valent pneumococcal conjugate vaccine. Section 4.2 Posology and method of administration is updated to cross reference to section 5.1. In addition, the MAH took the opportunity to add in section 4.4 Special warnings and precautions of the SmPC a statement regarding the sodium content, in line with the guideline on "Excipients in the labelling and package leaflet of medicinal product for human use" and to update the list of local representatives in the Package Leaflet." Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
TAKHZYRO - lanadelumab - EMEA/H/C/004806/II/0022, Orphan Shire Pharmaceuticals Ireland Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Kirsti Villikka, "update to the SmPC sections 4.8 and 5.1 to reflect the result of study DX-2930-04 (HELP Study ExtensionTM:An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE)). The Risk Management Plan is also updated following the completion of study DX-2930-04 and according to GVP Module V Rev 2 Integrated RMP template. In addition, the MAH is taking the opportunity to include a refrigeration statement for the multi-pack pre-filled syringe in the SmPC and pre-filled syringe PIL in section 6.4."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 16.09.2021.	
Truvada - emtricitabine / tenofovir disoproxil - EMEA/H/C/000594/II/0172 Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, "Submission of the final report from study GS-US-276-0104, listed as a category 3 study in the RMP. This is a Pooled Observational Study of pre-exposure prophylaxis (PrEP) users who took Truvada for PrEP, designed to collect and analyse data to examine the association between levels of adherence to the once-daily dosing regimen and risk of seroconversion, resistance development, and renal and skeletal adverse events." Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Veltassa - patiromer - EMEA/H/C/004180/II/0024 Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, "Update of section 4.2 of the SmPC in order to update the posology with information to add the option to use various liquids and soft foods instead of the currently approved options (water, apple, cranberry juice) for preparation of Veltassa oral suspension. This is based on results from a new compatibility study report of Veltassa with juices/liquids and soft foods (REP074062TC). The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Vfend - voriconazole - EMEA/H/C/000387/II/0142/G Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.3, 4.4 and 4.5 of the SmPC in order to add new contraindications to naloxegol and tolvaptan and add a Drug-Drug Interaction with lurasidone, include clarification text regarding adrenal insufficiency and Cushing's syndrome to the warnings and precautions for use, and re-order some of the drug-drug interaction information, respectively. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to correct an oversight from a previous procedure in the labelling (addition of the excipient sodium benzoate in section 3 of	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

the outer and inner label for the Powder for oral suspension in line with SmPC section 2 and PL sections 2 and 6).” Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 22.07.2021, 20.05.2021.	
Vfend - voriconazole - EMEA/H/C/000387/II/0143 Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Alexandre Moreau, “Update of sections 4.4 and 4.5 of the SmPC in order to add a new warning on co-administration with glasdegib and add drug-drug interaction information with eszopiclone, glasdegib, tretinoin and tyrosine kinase inhibitors metabolised by CYP3A4; the Package Leaflet is updated accordingly.” Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 08.07.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Xagrid - anagrelide - EMEA/H/C/000480/II/0091 Shire Pharmaceuticals Ireland Limited, Rapporteur: Alexandre Moreau, “C.I.4 Update of section 4.4 of the SmPC in order to add a new warning on the risks of fatal thrombotic complications associated with abrupt treatment discontinuation based on Due to New Pharmacovigilance data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to perform a minor editorial change in section 4.2.” Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
ZABDENO - ebola vaccine (rDNA, replication-incompetent) - EMEA/H/C/005337/II/0003 Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, “Update of section 4.8 of the SmPC to include ”febrile seizures" on the list of adverse drug reactions (ADRs) with frequency ”rare”, based on the review of febrile seizures post-marketing cases received within the GMS Global Safety Database. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the local representatives for HU and UK.” Opinion adopted on 02.09.2021. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

on 28.05.2021.	
WS2035 **Prezista-** **EMEA/H/C/000707/WS2035/0110** **Rezolsta-** **EMEA/H/C/002819/WS2035/0041** **Symtuza-** **EMEA/H/C/004391/WS2035/0032** Janssen-Cilag International NV, Lead Rapporteur: Johann Lodewijk Hillege, " To update section 4.5 of the SmPC to provide guidance on drug-drug interaction between cutaneously-administered corticosteroids and boosted darunavir, darunavir/cobicistat and darunavir/cobicistat/emtricitabine/tenofovir alafenamide, based on recent scientific literature publication. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet and to include minor editorial updates in the Product Information consisting of formatting, spelling and typo corrections." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 01.07.2021, 09.04.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2039 **Genvoya-** **EMEA/H/C/004042/WS2039/0076** **Stribild-EMEA/H/C/002574/WS2039/0116** **Tybost-EMEA/H/C/002572/WS2039/0058** Gilead Sciences Ireland UC, Lead Rapporteur: Bruno Sepodes, "Update of section 4.5 of the SmPC to add new information about the drug-drug interactions between cobicistat containing products (Genvoya, Tybost and Stribild) and corticosteroids, based on post-marketing data. Furthermore, the MAH took the opportunity to bring the Tybost Product Information in line with version 10.2 of the QRD template and update the list of local representatives. Moreover, minor editorial updates and corrections have been introduced throughout the Product Information of all three products." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 03.06.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2067 **Keppra-EMEA/H/C/000277/WS2067/0194**	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP

UCB Pharma S.A., Lead Rapporteur: Karin Janssen van Doorn, "Update of section 4.8 of the SmPC to include predisposition of the Japanese population to neuroleptic malignant syndrome (NMS). The package leaflet is to be updated accordingly. In addition, the MAH takes the opportunity to introduce further editorial changes in the labelling and update the contact details of the MAH in the package leaflet. The PI is brought in line with the latest QRD template version 10.2. This procedure also includes NAPs as listed in Annex B." Opinion adopted on 02.09.2021.	Members were in agreement with the CHMP recommendation.
WS2085 **Kaftrio-EMEA/H/C/005269/WS2085/0014** **Kalydeco-EMEA/H/C/002494/WS2085/0099** Vertex Pharmaceuticals (Ireland) Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Martin Huber, "Update of SmPC sections 4.4 and 4.8 following cases of liver failure in the post marketing setting. The PL is updated accordingly. The RMP version 3.1 is submitted for Kaftrio." Request for Supplementary Information adopted on 16.09.2021, 24.06.2021.	Request for supplementary information adopted with a specific timetable.
WS2130/G **Elebrato Ellipta-EMEA/H/C/004781/WS2130/0023/G** **Temybric Ellipta-EMEA/H/C/005254/WS2130/0011/G** **Trelegy Ellipta-EMEA/H/C/004363/WS2130/0020/G** GlaxoSmithKline Trading Services Limited, Lead Rapporteur: Peter Kiely, "Update of section 4.8 of the SmPC to add the ADR (dysgeusia') and change frequencies for already reported ADRs ('nasopharyngitis', 'viral respiratory tract infection', and 'dysphonia') based on an updated safety analysis. The PL is updated accordingly." Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.

B.5.3. CHMP-PRAC assessed procedures

Adenuric - febuxostat - EMEA/H/C/000777/II/0062 Menarini International Operations Luxembourg	Request for supplementary information adopted with a specific timetable.

S.A., Rapporteur: Andrea Laslop, PRAC Rapporteur: Jan Neuhauser, "C.I.4 - Update of sections 4.4 and 4.5 of the SmPC in order to amend an existing warning on the drug-drug interaction information with mercaptopurine/azathioprine based on final results from study FAI-01 listed as a category 3 study in the RMP; this is a phase I, drug-drug interaction study investigating the PK profile of 6-mercaptopurine following coadministration of two doses febuxostat and azathioprine in healthy subjects. The RMP version 9.0 has also been submitted." Request for Supplementary Information adopted on 16.09.2021.	
Bosulif - bosutinib - EMEA/H/C/002373/II/0050/G Pfizer Europe MA EEIG, Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to reflect results from the studies B1871039 (SOB) and B1871040 (category 3); study B1871039 is A Phase 4 Safety and Efficacy Study of Bosutinib in Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One or More Tyrosine Kinase Inhibitors and study B1871040 is An Open-Label Bosutinib Treatment Extension Study for Subjects With Chronic Myeloid Leukemia (CML) who Have Previously Participated in Bosutinib Studies B1871006 or B1871008. The Package Leaflet is updated accordingly. The MAH request deletion of the SOB from annex II of the PI and request consideration for switch of the Conditional Marketing Authorisation to a full Marketing Authorisation. The RMP version 6.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives for Belgium, Luxemburg, Germany and Northern Island in the Package Leaflet. The MAH is also asking the deletion of the product from the additional monitoring list." Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable. See 9.1
Bridion - sugammadex - EMEA/H/C/000885/II/0042 Merck Sharp & Dohme B.V., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka,	Request for supplementary information adopted with a specific timetable.

"C.I.3 type II to update sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to change posology recommendations and update safety, efficacy and pharmacokinetic information in children and adolescents (2-17 years) following EMEA/H/C/0885/P46/025 and based on final results from study P089MK8616. This is a Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Paediatric Participants. In addition, the MAH took the opportunity to implement some minor editorial changes throughout the Product Information (section 4.4 of Annex I and Annex II). The Package Leaflet is updated in accordance and the MAH took the opportunity to update the list of local representatives. Version 7.2 of the RMP has also been submitted to incorporate changes due to the completeness of PN089 and the MAH took the opportunity to update the RMP with information on completed clinical studies PN089, PN146 and PN145 and to implement the RMP GVP Module V Rev 2 template." Request for Supplementary Information adopted on 16.09.2021.	
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0036 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.8 and 5.1 of the SmPC to include new information based on updated interim results from study C4591001. This was a phase 1/2/3, placebo-controlled, observer-blind, interventional, dose-finding, study to evaluate the safety, tolerability, immunogenicity and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals. The Package Leaflet is updated accordingly. The updated RMP (version 2.2) is also approved." Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Cosentyx - secukinumab - EMEA/H/C/003729/II/0076 Novartis Europharm Limited, Rapporteur: Outi	Request for supplementary information adopted with a specific timetable.

Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia, "C.I.4 - Update of sections 4.2 and 5.1 of the SmPC in order to introduce a new posology regimen for adult plaque psoriasis patients and psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis based on the final results study CAIN457A2324 and exposure-response modelling; this is a randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 kg or higher with moderate to severe chronic plaque-type psoriasis; the Package Leaflet is updated accordingly. The RMP version 9.0 has also been submitted." Request for Supplementary Information adopted on 16.09.2021, 24.06.2021.	See 9.1
Forxiga - dapagliflozin - EMEA/H/C/002322/II/0071 AstraZeneca AB, Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin, "Removal of the indication for 'the treatment of patients with Type 1 Diabetes Mellitus (T1DM) as an adjunct to insulin in patients with BMI ≥ 27 kg/m2 when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy' and related additional Risk Minimisation Measures from Annex II for Forxiga 5 mg film-coated tablets. As a consequence, affected sections of the SmPC of the 5 mg tablets are updated. The Package Leaflet is updated in accordance. A combined SmPC/ Package Leaflet with the 10 mg tablets has been submitted. The RMP version 26.1 and version 26.2 have also been submitted." Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0044/G, Orphan Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Annika Folin, "C.I.4 - Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include the administration of obinutuzumab as a short duration infusion (SDI) of approximately 90 minutes in patients with Follicular Lymphoma (FL), based on the end of induction safety and efficacy data from the ongoing Phase IV study MO40597 (GAZELLE);	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

the Package Leaflet is updated accordingly. The RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.11.z Update of RMP version 8.0 to: - change the due date for the submission of the final CSR for Category 3 study BO21223 (GALLIUM); - remove important identified risks as per the PRAC Assessment Report for the PSUR covering period 01Nov2018 to 30Oct2019 (Procedure no.EMEA/H/C/PSUSA/00010279/201910); - correction of clinical cut-off dates and trial exposure data from previously conducted studies" Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 24.06.2021.	
GIVLAARI - givosiran - EMEA/H/C/004775/II/0006, Orphan Alnylam Netherlands B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Martin Huber, "Type II C.I.4: Update of SmPC section 4.8 to add 'blood homocysteine increase' as a new ADR and update to SmPC section 4.4 to add a related warning. The package leaflet is being updated accordingly. RMP v1.1 is also being submitted: consequences of blood homocysteine increase is being added as a new important potential risk, the clinical and post-marketing exposure is being updated and the due dates for ALN-AS1-002 and ALN-AS1-003 final study reports are being postponed. In addition, the MAH took the opportunity to make editorial changes to the Product Information in other EU languages and to update the contact number of the local representatives for Malta and Cyprus." Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Jyseleca - filgotinib - EMEA/H/C/005113/II/0006 Gilead Sciences Ireland UC, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "C.I.4 - Update of sections 4.5 and 5.2 of the SmPC in order to reflect new pharmacokinetic information on the effect of	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

filgotinib on OATP/CYP3A, OATP/BCRP, and OATP substrates based on final results from study GS-US-417-5937; this is a Phase 1, randomized, two-way crossover, open-label, single and multiple dose, single center study to evaluate the effect of filgotinib on a mixed OATP/CYP3A, OATP/BCRP, and OATP substrates using phenotypic probes; the Package Leaflet is updated accordingly. The RMP version 2.1 is accepted." Opinion adopted on 16.09.2021.	
Lamzede - velmanase alfa - EMEA/H/C/003922/II/0018, Orphan Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jan Neuhauser, "Type II C.I.4 Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to amend an existing warning on immunogenicity, update the summary of the safety profile, add cyanosis to the list of adverse drug reactions (ADRs) with frequency 'common', add the information that the safety profile observed in children under age 6 is consistent with what was observed in previous studies, update the pharmacodynamic properties. These proposed SmPC updates are based on the final results of rhLAMAN-08 study, which is listed as an Annex II study in the RMP, and is a 24-month multi-center, open-label phase II trial investigating the safety and efficacy of repeated velmanase alfa (recombinant human alpha-mannosidase) treatment in paediatric patients <6 years if age with alpha-mannosidosis. The Package Leaflet is being update accordingly. The RMPv8.1 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with QRD template v10.1 and v10.2." Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 20.05.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Lenvima - lenvatinib - EMEA/H/C/003727/II/0045 Eisai GmbH, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Annika Folin, "Submission of CSR of the Phase 2 multicentre, randomized, double-blind, non-inferiority trial in Subjects with 131I-Refractory Differentiated Thyroid Cancer to evaluate whether an oral starting dose of 18 mg daily will provide	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

comparable efficacy to a 24 mg starting dose with an improved safety profile (study E7080-G000-211) in fulfilment of the MEA 005.5. The RMP version 12.3 is updated accordingly." Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 08.07.2021.	
Mavenclad - cladribine - EMEA/H/C/004230/II/0020 Merck Europe B.V., Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "C.I.4 Type II Update of sections 4.2 and 4.4 of the SmPC in order to change posology recommendations by adding an advice on preventive measures to avoid liver injury and to add a new warning on liver function and liver injury based on a review of post-approval data in MAH's safety database, non-clinical and clinical trial data and scientific literature (cladribine and liver injury and epidemiological data on hepatic injury in MS). The Package Leaflet is updated accordingly. The RMP version 1.6 has also been submitted." Request for Supplementary Information adopted on 02.09.2021, 10.06.2021.	Request for supplementary information adopted with a specific timetable.
Naglazyme - galsulfase - EMEA/H/C/000640/II/0086 BioMarin International Limited, Rapporteur: Fátima Ventura, PRAC Rapporteur: Ana Sofia Diniz Martins, "C.I.11.b variation to update the RMP to version 6.4 to remove gastrointestinal haemorrhage, hepatic impairment and thrombocytopenia from the list of important potential risks. This proposed update is supported by the submission of the final report from the MPS VI Clinical Surveillance Program (CSP) listed as a Specific Obligation (SOB002) in the Annex II of the Product Information for this MAA under exceptional circumstances. This observational CSP was undertaken to characterise the natural progression of MPS VI; to evaluate the long-term safety and efficacy data from Naglazyme treatment; to collect information on the effect of Naglazyme treatment on lactation, growth and development of infants of Naglazyme treated mothers; and to evaluate the effects of Naglazyme treatment on children under 5 years of age." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 16.09.2021.	
NINLARO - ixazomib - EMEA/H/C/003844/II/0033, Orphan Takeda Pharma A/S, Rapporteur: Armando Genazzani, PRAC Rapporteur: Annika Folin, "C.I.11 Submission of the final report for the final analysis of OS for study C16010 listed as an obligation in the Annex II of the Product Information. This is a phase 3, randomized, double-blind to evaluate ixazomib in combination with LenDex in adult patients with relapsed and/or refractory multiple myeloma. The Annex II and the RMP (submitted version 7.0) are updated accordingly." Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0022/G Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.4, 4.8 and 5.1 of the SmPC based the final study report from study 14-505 (ANNEXA-4). This is a Prospective, open-label study of andexanet alfa in patients receiving a factor Xa inhibitor who have acute major bleeding to confirm safety and efficacy in patients with acute major bleeds. The provision of this study report fulfils Specific Obligation 001, and as a consequence it has been deleted in the Annex II. The package leaflet was updated accordingly, and the applicant took the opportunity to implement editorial changes in the Annexes. The revised RMP version 2.4 has also been submitted. Change to the summary of pharmacovigilance system due to change in QPPV." Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
Ontruzant - trastuzumab - EMEA/H/C/004323/II/0036 Samsung Bioepis NL B.V., Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Submission of the final report from clinical study (SB3-G31-BC-E) listed as a category 3 study in the RMP. This is an observational cohort study assessing the long-term cardiac safety (for Cardiac Safety and Survival Cohort) and survival (Survival Only Cohort and Cardiac Safety and Survival Cohort)	Request for supplementary information adopted with a specific timetable.

in patients who received treatment in study SB3-G31-BC. The RMP version 5.0 is also provided." Request for Supplementary Information adopted on 02.09.2021.	
OPDIVO - nivolumab - EMEA/H/C/003985/II/0105 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on final results from study CA209205 listed as a PAES in the Annex II; this is a Phase 2, open-label, multi-cohort, single-arm study of nivolumab in patients with classical Hodgkin's Lymphoma; The RMP version 20.3 has also been submitted. In view of the data submitted with the variation, amendments to Annex(es) I and II and to the Risk Management Plan are recommended. The following obligation has been fulfilled, and therefore it is recommended that it be deleted from the Annex II to the Opinion: 1. Post authorisation efficacy study (PAES): The MAH should submit the addendum to the CA209205 Final CSR reporting the OS data and data from the discontinuation schedule in Cohort C." Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation. See 9.1
Perjeta - pertuzumab - EMEA/H/C/002547/II/0059 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Anette Kirstine Stark, "Submission of the final clinical study report for the following clinical trial WO29217 (BERENICE), a multicenter, multinational, Phase II study to evaluate Perjeta in combination with Herceptin and standard neoadjuvant anthracycline-based chemotherapy in patients with HER2 positive, locally advanced, inflammatory, or early-stage breast cancer. The version 14.0 of the EU RMP is updated." Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Praluent - alirocumab - EMEA/H/C/003882/II/0065 sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of section 5.1 of the SmPC in order to include information on the effect of alirocumab on the neurocognitive	Request for supplementary information adopted with a specific timetable.

function based on final results from the study R727-CL-1532 listed as a category 3 study in the RMP; this is an interventional study to evaluate the neurocognitive function during the treatment, as well as the effect of the medicinal product in comparison with placebo on lipoproteins and to assess the safety and tolerability. The RMP version 6.0 has also been submitted." Request for Supplementary Information adopted on 02.09.2021.	
Pyramax - pyronaridine / artesunate - EMEA/H/W/002319/II/0023/G Shin Poong Pharmaceutical Co., Ltd., Rapporteur: Jean-Michel Race, PRAC Rapporteur: Tiphaine Vaillant, "Grouping of variations providing the final clinical study reports (CSR) of two completed studies: - Study SP-C-021-15: A Phase IIIb/IV cohort event monitoring study conducted in Central Africa to evaluate the safety in patients after the local registration of Pyramax (CANTAM study). This study is a Category 3 Required Additional Pharmacovigilance Activity described in the RMP (MEA 013). - SP-C-026-18: A Randomized Open-Label Exploratory Study to Determine The Efficacy of Different Treatment Regimens of Pyramax (Pyronaridine-Artesunate) In Asymptomatic Carriers Of Plasmodium Falciparum Monoinfections. This non-imposed study was conducted in The Gambia and Zambia and compared asymptomatic subjects with parasitaemia dosed according to the approved label of 3-day dosing with 2-day and 1-day dosing. There have been no new safety findings from the study but the RMP has been updated to reflect its details. As a result of the additional clinical data, corresponding changes to the Product Information (SmPC and PL) are proposed with the Grouping. RMP version 17 has also been submitted, updated to reflect the results of both above-mentioned CSRs, and converted to the new RMP integrated template format (Rev 2.0.1)." Request for Supplementary Information adopted on 02.09.2021, 06.05.2021, 14.01.2021.	Request for supplementary information adopted with a specific timetable.
Qarziba - dinutuximab beta -	Positive Opinion adopted by consensus on

EMEA/H/C/003918/II/0027/G, Orphan EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski, "-A.6 - Type IA - ATC code change to L01XC16 according to the WHO -C.I.4: Type II- Update of section 4.8 of the SmPC in order to include changes to the overall incidence of reported adverse reactions based on post-marketing data. In addition, minor changes are introduced in the Summary of Product Characteristics, Package Leaflet and Labelling in order to harmonise the Product Information with other regulatory regions. -C.I.11.b: Type II-Submission of RMP version 10.00 in order to include an alignment to post-marketing data (PSUR6) and to introduce updates on the important identified risks and important potential risks. In addition, some linguistic corrections are included on Swedish, Finnish, Italian, Spanish, and Portuguese EMA annexes." Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 22.07.2021.	16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
REKAMBYS - rilpivirine - EMEA/H/C/005060/II/0004 Janssen-Cilag International N.V., Rapporteur: Jean-Michel Race, PRAC Rapporteur: Liana Gross-Martirosyan, "Update of section 4.2 (to change posology recommendations) and sections 4.8, 5.1 and 5.2 of the SmPC (to update safety and efficacy information) based on week 124 results from the FLAIR study. This is a Phase III, randomized, open-label study to evaluate the efficacy, safety and tolerability of the combined treatment Cabotegravir and Rilpivirine. The Package Leaflet has been updated accordingly. Editorial changes and corrections have been carried out throughout the PI. The RMP version 3.1 has also been submitted." Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Rinvoq - upadacitinib - EMEA/H/C/004760/II/0009 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur:	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Nikica Mirošević Skvrce, "C.I.4 - Update of sections 4.4 and 5.1 of the SmPC in order to amend the existing warning on vaccination based on the final results from vaccination substudy (within study M13-538) listed as a category 3 study in the RMP; this is an open-label extension to assess the impact of upadacitinib treatment with a stable background of methotrexate on immunological responses following administration of a pneumococcal vaccine in rheumatoid arthritis patients. The RMP version 5.0 has also been submitted." Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 24.06.2021, 25.03.2021.	
Steglujan - ertugliflozin / sitagliptin - EMEA/H/C/004313/II/0015 Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC for Steglujan in order to update clinical information following final results from the VERTIS CV study (protocol 8835-004/B1521021) listed as a category 3 study in the RMP. This is a multi-centre, multi-national, randomised, double-blind, placebo-controlled study to evaluate the effect of ertugliflozin on cardiovascular risk in adult patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to include an editorial change in section 4.1 of the SmPC." Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 24.06.2021, 25.02.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Symtuza - darunavir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004391/II/0037 Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins, "Submission of the final report from final clinical study results GS-US-292-0109 listed as a category 3 study in the RMP. This is a Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Virologically-Suppressed, HIV-1 Positive Subjects final safety and efficacy. The RMP version 7.2 has also been submitted." Opinion adopted on 02.09.2021.	
TECFIDERA - dimethyl fumarate - EMEA/H/C/002601/II/0069/G Biogen Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "C.I.4 type II variation: Update of section 4.8 of the SmPC in order to add rhinorrhoea to the list of adverse drug reactions (ADRs) with frequency unknown based on a systematic review of information from clinical and non-clinical studies, post-marketing data and scientific literature. The Package Leaflet has been updated accordingly. C.I.4 type II variation: Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study 109MS303 (ENDORSE) listed as a category 3 study in the RMP. This is a dose-blind, multicenter, extension study to determine the long-term safety and efficacy of two doses of BG00012 monotherapy in subjects with Relapsing-Remitting Multiple Sclerosis. The RMP version 11.1 has also been submitted." Request for Supplementary Information adopted on 02.09.2021, 08.07.2021, 06.05.2021, 14.01.2021.	Request for supplementary information adopted with a specific timetable.
Tremfya - guselkumab - EMEA/H/C/004271/II/0028 Janssen-Cilag International N.V., Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Brigitte Keller-Stanislawski, "C.I.4 Update of sections 4.8 and 5.1 of the SmPC in order to update the EU product information with 5 years data from the final study reports of pivotal psoriasis studies PSO3001 and PSO3002 listed as additional PV activities (category 3 studies) in the RMP; in the long term extension part of these studies subjects received open-label guselkumab q8w, starting at Week 52 in PSO3001 and at Week 76 in PSO3002, with the last dose at Week 252 and the last safety follow-up visit at Week 264. The RMP version 8.1 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 02.09.2021, 10.06.2021.	
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0026 AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, "Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to include updated efficacy and safety information based on primary analysis from study D8110C00001 listed as a specific obligation in Annex II; this is a phase III randomised, double-blind, placebo-controlled, multicenter study in adults to determine the safety, efficacy and immunogenicity of Vaxzevria; the Package Leaflet and Annex II are updated accordingly. The updated RMP Version 3 Succession 2 has also been submitted." Request for Supplementary Information adopted on 16.09.2021, 22.07.2021.	Request for supplementary information adopted with a specific timetable. See 9.1
Vocabria - cabotegravir - EMEA/H/C/004976/II/0004 ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber, "Update of section 4.2 (to change posology recommendations) and sections 4.4, 4.8, 5.1 and 5.2 of the SmPC (to update safety and efficacy information) based on week 124 results from the FLAIR study. This is a Phase III, randomized, open-label study to evaluate the efficacy, safety and tolerability of the combined treatment Cabotegravir and Rilpivirine. The Package Leaflet has been updated accordingly. Editorial changes and corrections have been carried out throughout the PI. The RMP version 2 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet to bring the PI in line with the latest QRD template version 10.2." Opinion adopted on 16.09.2021. Request for Supplementary Information adopted on 22.07.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Xeljanz - tofacitinib - EMEA/H/C/004214/II/0028 Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, "Update of section 4.4 of the SmPC and annex IID of the product information based on the submission of the final report on	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Biospecimen testing study, listed as a category 3 study in the RMP. This is an exploratory study to assess biomarkers related to VTE events in study A3921133. The RMP version 14.4 has also been submitted. The requested variation proposed amendments to the Summary of Product Characteristics, Package Leaflet to the Risk Management Plan (RMP)." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 08.07.2021, 14.01.2021.	
Zeposia - ozanimod - EMEA/H/C/004835/II/0005 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon, "C.I.4 Type II Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on Progressive Multifocal Leukoencephalopathy (PML) and to add PML to the list of adverse drug reactions (ADRs) with rare frequency based on a PML case observed with ozanimod treatment in the RPC01-3001 open-label extension (OLE) study in patients with Multiple Sclerosis. The Package Leaflet (sections 2 and 4) is updated accordingly. The RMP version 1.3 has also been submitted." Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2098 **Komboglyze- EMEA/H/C/002059/WS2098/0051** **Onglyza- EMEA/H/C/001039/WS2098/0053** AstraZeneca AB, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Menno van der Elst, "Submission of the final report from study D1680C00016 (MEASURE HF) (listed as a category 3 study in the RMP). This is a 24-week, multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the effects of saxagliptin and sitagliptin on cardiac dimensions and function in patients with Type 2 Diabetes Mellitus and Heart Failure. The combined RMP for Komboglyze and Onglyza version 16 has also been submitted." Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.

B.5.4. PRAC assessed procedures

PRAC Led **Alecensa - alectinib - EMEA/H/C/004164/II/0033** Roche Registration GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Jana Lukacisinova, PRAC-CHMP liaison: Ondřej Slanař, "Submission of an updated RMP version 3.1 in order to remove the safety concern of missing information - long term safety, based on a report of the cumulative safety data from the pivotal Phase III clinical trial ALEX (BO28984). In addition, the MAH has taken the opportunity to update the RMP to remove study BO40643 from the pharmacovigilance plan, following assessment in procedure EMEA/H/C/004164/II/0030." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 06.05.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Conbriza - bazedoxifene - EMEA/H/C/000913/II/0054** Pfizer Europe MA EEIG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Update of the Risk Management Plan (RMP) to include updated study milestones and to revise the RMP format in line with latest Good Pharmacovigilance Practices Guidance Module V, revision 2 guidelines." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **COVID-19 Vaccine Janssen - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0014** Janssen-Cilag International N.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Update of section 4.8 of the SmPC in order to include diarrhoea and paraesthesia as adverse drug reactions (ADRs) with frequency uncommon; and hypoesthesia, lymphadenopathy, vomiting and tinnitus as ADRs with frequency rare, as requested by PRAC from post-authorisation measures MEA 014.2 and MEA 014.3 (3rd and 4th Monthly	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Summary Safety Report covering May 2021 and June 2021, respectively). In addition, the MAH took the opportunity to add editorial changes on sections 6.4 and 6.6 of the SmPC in line with the WHO recommendations. Also, the labelling has been updated to improve readability. The labelling and package leaflet are updated accordingly." Opinion adopted on 02.09.2021.	
PRAC Led **Dapivirine Vaginal Ring 25 mg - dapivirine - EMEA/H/W/002168/II/0011** International Partnership for Microbicides Belgium AISBL, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Jan Neuhauser, PRAC-CHMP liaison: Andrea Laslop, "Submission of the final report from study/studies MTN-16 listed as a category 3 study in the RMP. This is an observational study in women who became pregnant in the Phase III trial MTN-020 (ASPIRE) and the open-label extension study MTN-025 (HOPE) and who subsequently enrolled in the MTN-016 (EMBRACE) study. This study assessed the pregnancy and delivery outcomes in these women and infant follow up for the first year of life. The RMP version 0.8 has also been submitted." Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Enbrel - etanercept - EMEA/H/C/000262/II/0244** Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "C.I.13: Submission of the final report from study B1801310 (BIKER), listed as a category 3 study in the RMP. This is an observational Post-Authorisation Safety Study (PASS) of Etanercept and Methotrexate in the treatment of Juvenile Idiopathic Arthritis (JIA) using data obtained from participants in the German Biologics JIA Registry (BIKER) to monitor long-term safety and effectiveness of etanercept in the treatment of JIA in regular clinical practice." Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led	Request for supplementary information adopted

Eylea - aflibercept - EMEA/H/C/002392/II/0075 Bayer AG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of this type II variation as response to commitment undertaken in procedure II/68 covering the following elements: 1) validation of a follow-up questionnaire on Intraocular pressure (IOP) increase, 2) simplification of the educational material (prescriber guide and injection video) based on the data being collected and after the consultation with the panel of ophthalmologists, 3) RMP submission to include follow-up questionnaire on IOP increase and timing of IOP increase report submission" Request for Supplementary Information adopted on 02.09.2021.	with a specific timetable.
PRAC Led **Hemlibra - emicizumab - EMEA/H/C/004406/II/0025** Roche Registration GmbH, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ilaria Baldelli, PRAC-CHMP liaison: Armando Genazzani, "Update of sections 4.4, 4.8 and 5.1 of the Product information concerning immunogenicity and loss of efficacy due to anti-emicizumab antibodies. The RMP (v.3.0) is proposed to be updated accordingly." Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **HyQvia - human normal immunoglobulin - EMEA/H/C/002491/II/0070/G** Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "C.I.4 - Update of section 4.6 of the SmPC in order to update information on pregnancy and breast-feeding based on the final results from study 161301 listed as a category 3 study in the RMP; this is an observational study to collect long-term safety data from women treated with HyQvia. The package leaflet has been updated accordingly. RMP version 12.0 has also been submitted. In addition, the MAH took the opportunity to	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

implement minor corrections and editorial changes to the SmPC. C.I.11.b – Submission of an updated RMP version 12.0 to update the educational material section Part V.2, additional Risk Minimisation Measures, for HyQvia. The change was agreed by the PRAC in the outcome of the PSUSA procedure EMEA/H/C/PSUSA/00001633/202005." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 10.06.2021.	
PRAC Led **InductOs - dibotermin alfa - EMEA/H/C/000408/II/0100** Medtronic BioPharma B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Pieter de Graeff, "C.I.11.b - Submission of an updated RMP version 2.1 in order to submit the final study report from study EUPAS32916 listed as category 3 study in the RMP. This is an observational study to evaluate the effectiveness of additional Risk Minimisation Measures for InductOs. In addition, the MAH took the opportunity to submit study protocol for study EUPAS32916 that was agreed by PRAC and to update section 4.4 of the SmPC to add the traceability statement for biological medicinal products." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 10.06.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Lyxumia - lixisenatide - EMEA/H/C/002445/II/0033** sanofi-aventis groupe, Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report of study EUPAS 19769, a Post-authorisation Safety Study (PASS) included as a category 3 study in the RMP. The submission of this report addresses MEA 008.5. This is a registry to monitor the occurrences of events of interest including acute pancreatitis, pancreatic cancer and thyroid cancer, especially medullary carcinoma of the thyroid, among adult type 2 diabetes patients treated with lixisenatide using the data from national	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

registers and databases in Italy and Belgium. The updated RMP version 7.0 has also been submitted." Opinion adopted on 02.09.2021.	
PRAC Led **Neulasta - pegfilgrastim - EMEA/H/C/000420/II/0116** Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final report from study 20170701 listed as a category 3 study in the RMP. This is an observational study to assess the effectiveness of the Neulasta patient alert card and to measure medication errors related to the use of the On-Body Injector. The RMP version 8.0 has also been submitted." Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Norvir - ritonavir - EMEA/H/C/000127/II/0161** AbbVie Deutschland GmbH & Co. KG, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 7.3 in order to comply with revision 2 of the template. In addition, the MAH reviewed the information contained in the Norvir RMP and made the following updates: -Removal of important identified risk of toxicity of Norvir oral solution in preterm neonates -Removal of missing information regarding use of ritonavir in elderly patients -Analysis of the Antiretroviral Pregnancy Registry (APR) data will be provided with the ritonavir PSUR" Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 10.06.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/II/0045** GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, PRAC Rapporteur: Sonja Hrabcik, PRAC-CHMP liaison: Andrea Laslop, "Update of section 4.4 of the SmPC and section	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

2 of the PL in order to add a new warning on an increased risk of Guillain-Barré Syndrome (GBS) after vaccination with Shingrix observed in a post-marketing observational study in individuals aged 65 years or older. The RMP version 5.1 has also been submitted. In addition, the MAH took the opportunity to make some editorial changes to the SmPC and to update the list of local representatives in the Package Leaflet. The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP)." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 10.06.2021.	
PRAC Led **Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0015/G** Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Hans Christian Siersted, PRAC-CHMP liaison: Kirstine Moll Harboe, "Grouped variation to address PRAC requests raised in the 2nd and 3rd Moderna Monthly Safety Summary Report (MSSR) procedures (EMEA/H/C/005791/MEA/011.1 and EMEA/H/C/005791/MEA/011.2 respectively: - C.I.3.b (Type II): Update of section 4.4 of the SmPC to provide additional safety information regarding hypersensitivity and anaphylaxis, as requested by the PRAC in the 2nd Monthly Safety Summary Report. The Package Leaflet is updated accordingly. - C.I.3.b (Type II): Update of section 4.8 of the SmPC to include 'Delayed injection site reaction' as an adverse reaction, with the frequency 'Common', as requested by the PRAC in the 3rd Monthly Safety Summary. The Package Leaflet is updated accordingly. In addition, the Marketing Authorisation Holder (MAH) submitted a justification for not adding diarrhoea to the PI as an adverse reaction, as requested by the PRAC in the 3rd Monthly Safety Summary Report, and took the opportunity to make minor editorial changes." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 02.09.2021, 08.07.2021.	
PRAC Led **Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0022** Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Hans Christian Siersted, PRAC-CHMP liaison: Kirstine Moll Harboe, ”Submission of an updated RMP version 2.0 to include clinical safety data from study mRNA-1273 P203 (NCT04649151), a Phase 2/3, randomised, observer-blind, placebo-controlled study evaluating the safety, reactogenicity, and effectiveness of the mRNA-1273 vaccine in healthy adolescents aged ≥ 12 to < 18 years.” Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0028** Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Hans Christian Siersted, PRAC-CHMP liaison: Kirstine Moll Harboe, “Submission of an updated RMP version 2.1 to include myocarditis and pericarditis as an important identified risk, as requested by PRAC as an outcome of the myocarditis and pericarditis signal assessment procedure.” Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Suliqua - insulin glargine / lixisenatide - EMEA/H/C/004243/II/0023** sanofi-aventis groupe, Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, “Submission of the final study report from the ”Patient registry of lixisenatide use in adult type 2 diabetes”, which is included as a category 3 PASS in the RMP. This study's objective is to monitor the occurrences of events of interest including acute pancreatitis, pancreatic cancer and thyroid cancer, especially medullary carcinoma of the thyroid (MCT), among adult type 2 diabetes patients treated with Lixisenatide using the data from national	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

registers and databases in Italy and Belgium. The provision of the study report addresses post-authorisation measure (PAM) MEA 005.3." Opinion adopted on 02.09.2021.	
PRAC Led **Truvada - emtricitabine / tenofovir disoproxil - EMEA/H/C/000594/II/0169** Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "Submission of an updated RMP (version 18.0) to remove from the Pharmacovigilance Plan - two completed category 3 studies (Study GS-US-276-0103 and Study GS-EU-276-4027) and - the category 3 additional pharmacovigilance activity for the registry study GS- EU- 276-4487 (a category 3 study in the RMP): a prospective, longitudinal, observational registry of emtricitabine/tenofovir disoproxil fumarate for human immunodeficiency virus 1 (HIV-1) pre-exposure prophylaxis (PrEP) in the European Union." Opinion adopted on 02.09.2021. Request for Supplementary Information adopted on 11.02.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **WS2064 Nuwiq-EMEA/H/C/002813/WS2064/0043 Vihuma-EMEA/H/C/004459/WS2064/0024** Octapharma AB, Lead PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "To provide an updated RMP to remove the completed studies GENA-05 and GENA-15. As a consequence, in the section 'Missing Information' the following safety concerns have been removed: "Safety in previously untreated patients", "Children < 2 years", and "Immune tolerance induction". No new safety concerns were added. In addition, the RMP has been updated to GVP Module V Rev.2." Request for Supplementary Information adopted on 02.09.2021, 10.06.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **WS2082 Efficib-EMEA/H/C/000896/WS2082/0101 Janumet-EMEA/H/C/000861/WS2082/0101 Januvia-**	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMEA/H/C/000722/WS2082/0075 **Ristaben-** **EMEA/H/C/001234/WS2082/0068** **Ristfor-EMEA/H/C/001235/WS2082/0089** **TESAVEL-** **EMEA/H/C/000910/WS2082/0075** **Velmetia-** **EMEA/H/C/000862/WS2082/0104** **Xelevia-EMEA/H/C/000762/WS2082/0080** Merck Sharp & Dohme B.V., Lead PRAC Rapporteur: Menno van der Elst, "To provide an updated RMP to reflect clinical trial exposure to sitagliptin in patients 10-17 years of age. In particular, to update the patient exposure data in the safety specifications Part II and implement the already assessed clinical data (variations for children 10-17 years) within finalised EMEA/H/C/WS1727 and EMEA/H/C/WS1898 procedures." Opinion adopted on 02.09.2021.	
PRAC Led **WS2115** **Humalog-** **EMEA/H/C/000088/WS2115/0191** **Liprolog-** **EMEA/H/C/000393/WS2115/0151** Eli Lilly Nederland B.V., Informed Consent of Humalog, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin, "To provide an updated RMP to reflect the completion of a routine pharmacovigilance activity related to a new manufacturing process ("oKPB") of insulin lispro. The final commitment report on that activity was submitted to the Agency on 29th April 2021. Additionally, the MAH took this opportunity to modify milestones for a post-approval safety surveillance programme for severe hypoglycaemia related to the use of a new presentation, the Tempo Pen. The current version of the EU RMP submission has been changed from '31 March 2021' to 'Within 6 months of first commercialisation'. Therefore, the final due date for this study report was amended as follows: 'Within 3 years of first commercialisation'. Finally, the status of a paediatric PK/PD study has been updated since it was completed. Furthermore, the marketing authorisation status	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

of Lyumjev has been added." Opinion adopted on 02.09.2021.	

B.5.5. CHMP-CAT assessed procedures

Alofisel - darvadstrocel - EMEA/H/C/004258/II/0027, Orphan, ATMP Takeda Pharma A/S, Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Kristina Dunder Opinion adopted on 16.09.2021, 10.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Zynteglo - betibeglogene autotemcel - EMEA/H/C/003691/II/0025, Orphan, ATMP bluebird bio (Netherlands) B.V, Rapporteur: Carla Herberts, CHMP Coordinator: Paula Boudewina van Hennik Opinion adopted on 16.09.2021, 10.09.2021. Request for Supplementary Information adopted on 18.06.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2071 **Tecartus- EMEA/H/C/005102/WS2071/0007** **Yescarta- EMEA/H/C/004480/WS2071/0039** Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Opinion adopted on 16.09.2021, 10.09.2021. Request for Supplementary Information adopted on 16.07.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

PRAC Led **Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0044, ATMP** Amgen Europe B.V., Rapporteur: Heli Suila, CHMP Coordinator: Johanna Lähteenvuo, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus,	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

"Submission of the final report from study 20180099 listed as a category 3 study in the RMP. This is a cross-sectional survey to evaluate physician knowledge of safety messages included in the physician education booklet (PEB) for Imlygic." Opinion adopted on 16.09.2021, 10.09.2021. Request for Supplementary Information adopted on 16.07.2021, 12.05.2021.	
PRAC Led **Yescarta - axicabtagene ciloleucel - EMEA/H/C/004480/II/0040, Orphan, ATMP** Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Sinan B. Sarac, "Submission of the final study report for the non-interventional study KT-EU-471-0116 (Quantitative Testing of Healthcare Provider Knowledge about Yescarta (axicabtagene ciloleucel) Risk Minimisation Measures) in fulfilment of an additional pharmacovigilance activity (category 3) listed in the EU Risk Management Plan for Yescarta." Request for Supplementary Information adopted on 10.09.2021.	Request for supplementary information adopted with a specific timetable.

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2089/G **Bretaris Genuair- EMEA/H/C/002706/WS2089/0047/G** **Eklira Genuair- EMEA/H/C/002211/WS2089/0047/G** AstraZeneca AB, Lead Rapporteur: Ewa Balkowiec Iskra Request for Supplementary Information adopted on 16.09.2021.	Request for supplementary information adopted with a specific timetable.
WS2090/G **Copalia HCT- EMEA/H/C/001159/WS2090/0093/G** **Dafiro HCT- EMEA/H/C/001160/WS2090/0095/G** **Exforge HCT- EMEA/H/C/001068/WS2090/0092/G** Novartis Europharm Limited, Lead Rapporteur:	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Kirstine Moll Harboe, The MAH took opportunity to introduce editorial changes in sections 3.2.P.3.2 and 3.2.P.3.3." Opinion adopted on 02.09.2021.	
WS2091 **Efficib-EMEA/H/C/000896/WS2091/0102** **Janumet-EMEA/H/C/000861/WS2091/0102** **Januvia-EMEA/H/C/000722/WS2091/0076** **Ristaben-EMEA/H/C/001234/WS2091/0069** **Ristfor-EMEA/H/C/001235/WS2091/0090** **TESAVEL-EMEA/H/C/000910/WS2091/0076** **Velmetia-EMEA/H/C/000862/WS2091/0105** **Xelevia-EMEA/H/C/000762/WS2091/0081** Merck Sharp & Dohme B.V., Lead Rapporteur: Johann Lodewijk Hillege, "To combine the SmPC as per QRD guidance, also the Package Leaflets were combined. The marketing authorisation holder also took the opportunity to align the PI to the latest QRD template (version 10.2). In addition, the details of the local representatives for BE, DE and LU were also updated." Opinion adopted on 16.09.2021.	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2093 **Perjeta-EMEA/H/C/002547/WS2093/0058** **Phesgo-EMEA/H/C/005386/WS2093/0006** Roche Registration GmbH, Lead Rapporteur: Sinan B. Sarac Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2094 **Infanrix hexa-EMEA/H/C/000296/WS2094/0302** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke, Opinion adopted on 09.09.2021.	Positive Opinion adopted by consensus on 09.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2099 **HyQvia-EMEA/H/C/002491/WS2099/0073** **Kiovig-EMEA/H/C/000628/WS2099/0111** Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus, Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
WS2101	Positive Opinion adopted by consensus on

Hexacima-EMEA/H/C/002702/WS2101/0118 **Hexyon-EMEA/H/C/002796/WS2101/0122** **MenQuadfi-EMEA/H/C/005084/WS2101/0007** Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus, Opinion adopted on 02.09.2021.	02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2104 **CABOMETYX-EMEA/H/C/004163/WS2104/0022** **Cometriq-EMEA/H/C/002640/WS2104/0046** Ipsen Pharma, Lead Rapporteur: Bjorg Bolstad, Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2106 **Actraphane-EMEA/H/C/000427/WS2106/0090** **Insulatard-EMEA/H/C/000441/WS2106/0088** **Mixtard-EMEA/H/C/000428/WS2106/0091** **NovoMix-EMEA/H/C/000308/WS2106/0109** **Protaphane-EMEA/H/C/000442/WS2106/0087** Novo Nordisk A/S, Lead Rapporteur: Kirstine Moll Harboe Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2108/G **Galvus-EMEA/H/C/000771/WS2108/0070/G** **Jalra-EMEA/H/C/001048/WS2108/0072/G** **Xiliarx-EMEA/H/C/001051/WS2108/0070/G** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2109 **Copalia-EMEA/H/C/000774/WS2109/0120** **Copalia HCT-EMEA/H/C/001159/WS2109/0094** **Dafiro-EMEA/H/C/000776/WS2109/0124** **Dafiro HCT-**	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMEA/H/C/001160/WS2109/0096 **Exforge-** **EMEA/H/C/000716/WS2109/0119** **Exforge HCT-** **EMEA/H/C/001068/WS2109/0093** Novartis Europharm Limited, Lead Rapporteur: Kirstine Moll Harboe, "To update Annex II of the PI related to the conditions of the Marketing Authorisation of Exforge (including its duplicates) and Exforge HCT (including its duplicates) as set out by the Commission Decision as an outcome of the assessment for the impact of the Article 5(3) scientific opinion on nitrosamines in human medicinal products on the opinion adopted pursuant to Article 31 of Directive 2001/83/EC for angiotensin-II-receptor antagonists (sartans) containing a tetrazole group. The MAH confirms the fulfilment of condition D and omission of the specification is justified by providing data as requested." Opinion adopted on 02.09.2021.	
WS2110/G **Afinitor-** **EMEA/H/C/001038/WS2110/0074/G** **Votubia-** **EMEA/H/C/002311/WS2110/0072/G** Novartis Europharm Limited, Lead Rapporteur: Janet Koenig Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2112 **Hexacima-** **EMEA/H/C/002702/WS2112/0119** **Hexyon-** **EMEA/H/C/002796/WS2112/0123** Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 02.09.2021.	Request for supplementary information adopted with a specific timetable.
WS2116/G **Kivexa-** **EMEA/H/C/000581/WS2116/0092/G** **Triumeq-** **EMEA/H/C/002754/WS2116/0096/G** **Trizivir-** **EMEA/H/C/000338/WS2116/0126/G** **Ziagen-** **EMEA/H/C/000252/WS2116/0121/G**	Request for supplementary information adopted with a specific timetable.

ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson, Request for Supplementary Information adopted on 09.09.2021.	
WS2117 **Entresto-** **EMEA/H/C/004062/WS2117/0040** **Neparvis-** **EMEA/H/C/004343/WS2117/0038** Novartis Europharm Limited, Lead Rapporteur: Johann Lodewijk Hillege, "To update Annex II of the PI related to the conditions to the Marketing Authorisation of Entresto and Neparvis as set out by the Commission Decision as an outcome of the assessment for the impact of the Article 5(3) scientific opinion on nitrosamines in human medicinal products on the opinion adopted pursuant to Article 31 of Directive 2001/83/EC for angiotensin-II-receptor antagonists (sartans) containing a tetrazole group. The MAH confirms the fulfilment of condition D and omission of the specification is justified by providing data as requested. Furthermore, the local contact details for the UK (Northern Ireland) is also being modified in section 6 of the PL." Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2123 **Blitzima-** **EMEA/H/C/004723/WS2123/0045** **Truxima-** **EMEA/H/C/004112/WS2123/0049** Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz, "To update section 6.6 of the SmPC to add new instructions for the injections in order to align the PI with its originator Mabthera during assessment and finalisation of procedure IB-181 adopted on February 2021. In addition, the MAH would like to include minor editorial changes in the Spanish and German annexes." Opinion adopted on 02.09.2021.	Positive Opinion adopted by consensus on 02.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS2124/G **Corbilta-** **EMEA/H/C/002785/WS2124/0024/G** **Levodopa/Carbidopa/Entacapone Orion-** **EMEA/H/C/002441/WS2124/0032/G** **Stalevo-**	Positive Opinion adopted by consensus on 16.09.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

EMEA/H/C/000511/WS2124/0094/G
Orion Corporation, Lead Rapporteur: Outi Mäki-Ikola,
Opinion adopted on 16.09.2021.

B.5.9. Information on withdrawn type II variation / WS procedure

B.5.10. Information on type II variation / WS procedure with revised timetable

PRAC Led **Beovu - brolucizumab - EMEA/H/C/004913/II/0008** Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC in order to include the description of intraocular inflammation, based on final results from a non-interventional retrospective real-world evidence study conducted in patients with neovascular (wet) age-related macular degeneration (nAMD) to better understand the incidence of adverse events/safety signal after initiating treatment with brolucizumab for up to 6 months." Request for Supplementary Information adopted on 10.06.2021.	The CHMP adopted a revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

formoterol fumarate dihydrate / glycopyrronium / budesonide - EMEA/H/C/005311
maintenance treatment of chronic obstructive pulmonary disease (COPD)

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

---

pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451

prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F
List of Questions adopted on 22.07.2021.

AYVAKYT - avapritinib - EMEA/H/C/005208/X/0004/G, Orphan

Blueprint Medicines (Netherlands) B.V., Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Menno van der Elst, "Extension application to add two new strengths of film-coated tablets (25 mg and 50 mg), grouped with a type II variation (C.I.6.a) to introduce a new therapeutic indication for AYVAKYT. Extension of indication to include treatment of adult patients with advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell leukaemia (MCL), after at least one systemic therapy for AYVAKYT based on the results of the BLU-285-2101 and BLU-285-2202 studies. The new indication is applicable to the new and existing presentations (25 mg, 50 mg, 100 mg and 200 mg film-coated tablets). As a consequence, sections 1, 2, 3, 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2, 5.3, 6.1 and 8 of the SmPC are updated. The Labelling and Package Leaflet are updated in accordance. Version 1.1 of the RMP has also been submitted."
List of Questions adopted on 24.06.2021.
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

---

dengue tetravalent vaccine (live, attenuated) - EMEA/H/W/005362, Article 58

prevention of dengue disease

List of Questions adopted on 24.06.2021.

Dupixent - dupilumab - EMEA/H/C/004390/X/0045/G

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola, "1- Extension of a marketing authorisation for Dupixent to add a new strength, 100 mg solution for injection.

2- Type II (C.I.6) - Extension of indication to include treatment of paediatric patients with severe asthma with type 2 inflammation aged 6 to 11 years old.
Version 6.0 of the RMP has also been submitted."
List of Questions adopted on 22.07.2021.

Epclusa - sofosbuvir / velpatasvir - EMEA/H/C/004210/X/0056/G

Gilead Sciences Ireland UC, Rapporteur: Filip Josephson, PRAC Rapporteur: Ana Sofia Diniz Martins, "Extension application to introduce a new pharmaceutical form (coated granules in sachet) associated with strengths 200 mg/50 mg and 150 mg/37.5 mg. The new presentations are indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older. The extension application is grouped with a type II variation (C.I.6.a) to include paediatric use in patients 3 years of age and older to the existing presentations of the film-coated tablets.
Sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication.
The RMP (version 7.1) is updated in accordance.
In addition, the MAH took the opportunity to implement minor updates and corrections throughout the Product Information."
List of Questions adopted on 22.07.2021.

betulae cortex dry extract (5-10: 1); extraction solvent: n-heptane 95% (w/w) - EMEA/H/C/005035, Orphan

Amryt Pharmaceuticals DAC, Treatment to achieve accelerated healing of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients from birth onwards.
List of Questions adopted on 22.07.2021.

gefapixant - EMEA/H/C/005476
treatment of refractory or unexplained chronic cough
List of Questions adopted on 24.06.2021.

gefapixant - EMEA/H/C/005884
treatment of refractory or unexplained chronic cough
List of Questions adopted on 24.06.2021.

somatrogon - EMEA/H/C/005633, Orphan
Pfizer Europe MA EEIG, indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.
List of Questions adopted on 24.06.2021.

dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/005155
prevention of dengue disease
List of Questions adopted on 24.06.2021.

pegfilgrastim - EMEA/H/C/004780
treatment of neutropenia
List of Questions adopted on 17.09.2020.

rimegepant - EMEA/H/C/005725
management of migraine
List of Questions adopted on 24.06.2021.

B.6.4. Annual Re-assessments: timetables for adoption

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Caprelsa - vandetanib - EMEA/H/C/002315/R/0050
Genzyme Europe BV, Rapporteur: Alexandre Moreau, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Tiphaine Vaillant

SIRTURO - bedaquiline - EMEA/H/C/002614/R/0045, Orphan
Janssen-Cilag International NV, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Abevmy - bevacizumab - EMEA/H/C/005327/II/0005/G Mylan IRE Healthcare Limited, Rapporteur: Jan Mueller-Berghaus	
Adakveo - crizanlizumab - EMEA/H/C/004874/II/0005, Orphan Novartis Europharm Limited, Rapporteur: Daniela Philadelphy	
Aranesp - darbepoetin alfa - EMEA/H/C/000332/II/0156 Amgen Europe B.V., Rapporteur: Martina Weise	
Bylvay - odevixibat - EMEA/H/C/004691/II/0001, Orphan Albireo, Rapporteur: Johann Lodewijk Hillege	
Cayston - aztreonam - EMEA/H/C/000996/II/0084 Gilead Sciences Ireland UC, Rapporteur: Johann Lodewijk Hillege	
Ceprotin - human protein C - EMEA/H/C/000334/II/0124/G Takeda Manufacturing Austria AG, Rapporteur: Jan Mueller-Berghaus	
Cinryze - human c1-esterase inhibitor - EMEA/H/C/001207/II/0089 Shire Services BVBA, Rapporteur: Jan Mueller-Berghaus	
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0063/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	See B.5.1
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0065/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	See B.5.1
COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0066 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	See B.5.1

COVID-19 Vaccine Janssen - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0017
Janssen-Cilag International N.V., Rapporteur: Christophe Focke

Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0009
Daiichi Sankyo Europe GmbH, Rapporteur: Sinan B. Sarac

Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0010
Daiichi Sankyo Europe GmbH, Rapporteur: Sinan B. Sarac

Entyvio - vedolizumab - EMEA/H/C/002782/II/0063/G
Takeda Pharma A/S, Rapporteur: Armando Genazzani

Herzuma - trastuzumab - EMEA/H/C/002575/II/0041/G
Celltrion Healthcare Hungary Kft., Rapporteur: Jan Mueller-Berghaus

Jakavi - ruxolitinib - EMEA/H/C/002464/II/0057/G
Novartis Europharm Limited, Rapporteur: Filip Josephson

Levetiracetam SUN - levetiracetam - EMEA/H/C/002051/II/0026
Sun Pharmaceutical Industries Europe B.V., Generic, Generic of Keppra, Rapporteur: Konstantinos Markopoulos

Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0066
Teva B.V., Rapporteur: Outi Mäki-Ikola

Mosquirix - plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) - EMEA/H/W/002300/II/0059/G
GlaxoSmithkline Biologicals SA, Rapporteur: Jan Mueller-Berghaus

Nulojix - belatacept - EMEA/H/C/002098/II/0076
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson

Rhokiinsa - netarsudil - EMEA/H/C/004583/II/0007/G

Aerie Pharmaceuticals Ireland Limited, Rapporteur: Jayne Crowe

Rixubis - nonacog gamma - EMEA/H/C/003771/II/0041/G
Baxalta Innovations GmbH, Rapporteur: Andrea Laslop

RoActemra - tocilizumab - EMEA/H/C/000955/II/0103/G
Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus

Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0035
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus

Zercepac - trastuzumab - EMEA/H/C/005209/II/0013/G
Accord Healthcare S.L.U., Rapporteur: Sol Ruiz

WS2135/G
Rixathon- EMEA/H/C/003903/WS2135/0052/G
Riximyo- EMEA/H/C/004729/WS2135/0053/G
Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus

WS2164/G
Blitzima- EMEA/H/C/004723/WS2164/0047/G
Truxima- EMEA/H/C/004112/WS2164/0051/G
Celltrion Healthcare Hungary Kft., Duplicate, Duplicate of Truxima, Lead Rapporteur: Sol Ruiz

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Adempas - riociguat - EMEA/H/C/002737/II/0033/G, Orphan
Bayer AG, Rapporteur: Johann Lodewijk Hillege,
"Group of variations:
Type II C.I.4. update to SmPC sections 4.8 and 5.1 based on the submission of the final clinical study reports of the Phase III long term extension study PATENT-2.
Type II C.I.4. update to SmPC sections 4.8 and 5.1 based on the submission of the final clinical study reports of the Phase III long term

extension study CHEST-2."

Cimzia - certolizumab pegol - EMEA/H/C/001037/II/0101
UCB Pharma S.A., Rapporteur: Kristina Dunder, "C.I.4: Update of section 4.6 of the SmPC in order to update information on pregnancy based on non-interventional data from the UCB Global Safety Database on prospective Cimzia-exposed pregnancies with known outcomes; the Package Leaflet is updated accordingly."

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0062
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2 and 4.4 of the SmPC in order to introduce a third dose of Comirnaty for individuals 12 years of age and older who are severely immunocompromised, based on published literature data; the Package Leaflet is updated accordingly."

COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0067
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to introduce a booster dose (third dose) of Comirnaty for individuals 18 years of age and older, based on interim safety and immunogenicity data from the interventional study C4591001, " A Phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals". The package leaflet is updated accordingly."

Copiktra - duvelisib - EMEA/H/C/005381/II/0002
Secura Bio Limited, Rapporteur: Sinan B. Sarac, "Update of section 5.1 of the SmPC based on the final overall survival results from study IPI-145-07, an interventional Phase 3 Study of duvelisib (IPI-145) vs ofatumumab in patients with relapsed or refractory Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma."

Cresemba - isavuconazole - EMEA/H/C/002734/II/0036, Orphan
Basilea Pharmaceutica Deutschland GmbH,

Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC in order to harmonise the EUCAST breakpoints to those published in the EUCAST breakpoint tables version 10.0, valid from 4 February 2020 for interpretation of minimum inhibitory concentrations (MICs) of antifungal agents. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."	
Dapivirine Vaginal Ring 25 mg - dapivirine - EMEA/H/W/002168/II/0012/G International Partnership for Microbicides Belgium AISBL, Rapporteur: Paula Boudewina van Hennik, "Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with vaginal products (e.g. vaginal miconazole) that are metabolised by CYP450 and UGT enzymes and to update pharmacokinetic information based on the final study reports of 3 in vitro transporter studies evaluating the interactions between dapivirine and transporters (study NPK/0025), dapivirine-miconazole interactions on cytochrome P450 (study NPK/0026) and UGT enzymes (study NPK/0027). Submission of the final report from study evaluating the impact of dapivirine and miconazole on cellular tight junctions and assessing the impact of miconazole on dapivirine tissue permeability (study NPK/0028). These 4 in vitro studies were submitted to fulfil post-authorisation measures (REC) requested in the initial marketing authorisation application assessment report."	
Empliciti - elotuzumab - EMEA/H/C/003967/II/0028 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Hennik, "C.I.4: Update of section 5.1 of the SmPC in order to update efficacy data from the final CSR for study CA204125. This is an Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in RRMM. In addition, the MAH took the opportunity to remove the list of local representatives in the Package Leaflet ."	
Epidyolex - cannabidiol - EMEA/H/C/004675/II/0015, Orphan	

GW Pharma (International) B.V., Rapporteur: Kirstine Moll Harboe, "Update of sections 4.5 and 5.1 of the SmPC to add drug-drug interaction information with everolimus and P-gp substrates following the assessment the study GWCP19195, a phase I open-label pharmacokinetic drug-drug interaction trial to investigate the effect of cannabidiol on the pharmacokinetics of everolimus in healthy subject. In addition, the MAH took the opportunity to introduce editorial updates in section 5.1 and section 4.9."

Epidyolex - cannabidiol - EMEA/H/C/004675/II/0016, Orphan

GW Pharma (International) B.V., Rapporteur: Kirstine Moll Harboe, "Update of section 5.3 of the SmPC to reflect on the conclusions of the study GWTX1504, 104-week oral (gavage) administration carcinogenicity study in mouse."

Evrysdi - risdiplam - EMEA/H/C/005145/II/0002, Orphan

Roche Registration GmbH, Rapporteur: Bruno Sepodes, "Update of sections 4.8 and 5.1 of the SmPC based on long-term results from study FIREFISH (BP39056) listed as a category 3 study in the RMP; this is an observational OLE safety and efficacy study. In addition, the MAH took the opportunity to introduce editorial changes to SmPC and to the Instruction for use (IFU)."

Fetcroja - cefiderocol - EMEA/H/C/004829/II/0006/G

Shionogi B.V., Rapporteur: Filip Josephson, "Submission of the final report from the in vitro RIS correlation study S-649266-PF-415-N (REC 003), to address CYP3A4 induction by cefiderocol.
In addition, the MAH submitted the final report of in vitro study S-649266-CPK-008-C to investigate the DDI between cefiderocol as a CYP3A4 inducer and Midazolam using physiologically-based pharmacokinetic model."

Imfinzi - durvalumab - EMEA/H/C/004771/II/0034

AstraZeneca AB, Rapporteur: Sinan B. Sarac, "Update of sections 4.4 and 4.8 of the SmPC in order to reflect the outcome of the re-defined process to identify and calculate immune-

mediated Adverse Event (imAE) rates from clinical study and pooled datasets within the durvalumab development programmes. In addition, the MAH implemented minor editorial corrections to sections 4.4 and 5.1 of the SmPC."	
Opsumit - macitentan - EMEA/H/C/002697/II/0043, Orphan Janssen-Cilag International N.V., Rapporteur: Maria Concepcion Prieto Yerro, "C.I.4: Update of sections 4.2 and 4.4 of the SmPC to remove a sentence and a warning on the limited clinical experience in patients over the age of 75 years, following the recommendation of the EMEA/H/C/PSUSA/00010115/202010 procedure to remove 'Elderly patients' as missing information in the RMP. The Package Leaflet is being updated accordingly. In addition, the MAH took this opportunity to update the Package Leaflet to include section on Male fertility and align it with the currently approved information in SmPC, sections 4.6 Fertility, pregnancy, and lactation and 5.3 Preclinical safety."	
Opsumit - macitentan - EMEA/H/C/002697/II/0044, Orphan Janssen-Cilag International N.V., Rapporteur: Maria Concepcion Prieto Yerro, "C.I.4: Update of SmPC sections 4.8 and 5.1, based on the long-term follow-up data from SERAPHIN open-label (OL) study. SERAPHIN OL study was a long-term single-arm open-label extension study of the SERAPHIN double-blind (DB) study, to assess the safety and tolerability of macitentan in patients with symptomatic pulmonary arterial hypertension (PAH) that have completed the DB study or that experienced a morbidity event and for who a written approval to roll over into the OL study was obtained by the sponsor."	
Plenadren - hydrocortisone - EMEA/H/C/002185/II/0034, Orphan Shire Services BVBA, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC to add bradycardia as a new ADR with frequency unknown."	
REKAMBYS - rilpivirine - EMEA/H/C/005060/II/0006 Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, "Update of section 4.4	

of the SmPC in order to amend an existing warning on section post-injections reactions, based on the availability of new information from ongoing phase 3/3b clinical trials. Section 2 of the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement some minor editorial changes."

Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0031

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "To update sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to introduce a third dose of Spikevax in the primary vaccination schedule for individuals 18 years of age and older who have undergone a solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise, based on updated clinical literature; the Package Leaflet is updated accordingly."

TAGRISSO - osimertinib - EMEA/H/C/004124/II/0045

AstraZeneca AB, Rapporteur: Blanca Garcia-Ochoa, "Update of section 5.3 of the SmPC in order to reflect the outcome of the 104 Week Oral (Gavage) Carcinogenicity Study (507363) in the Rat submitted as recommended by the CHMP."

Trumenba - meningococcal group B vaccine (recombinant, adsorbed) - EMEA/H/C/004051/II/0037

Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.8 and 5.1 of the SmPC in order to include inmuno-persistence and booster data based on final results from study B1971035 listed as a part of the paediatric investigation plan; this is a phase 2, randomized, controlled, observer-blinded study conducted to describe the immunogenicity, safety, and tolerability of Bivalent rLP2086 when administered to healthy toddlers aged 12 to <18 months or 18 to <24 months, and the safety and immunogenicity of a booster dose of Bivalent rLP2086."

Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type

b conjugate vaccine (adsorbed) -
EMEA/H/C/003982/II/0088

MCM Vaccine B.V., Rapporteur: Christophe Focke, "Update of section 5.1 of the SmPC in order to include information about long-term durability of the immune protection against HBV infection based on study V419-013 A Hepatitis B Vaccine Challenge Study to Demonstrate the Durability of Protection Against Hepatitis B Virus Infection in Healthy Children Vaccinated Approximately 9 Years Previously With a 2- or 3-Dose Infant Series and Toddler Dose of Vaxelis (study report P013V419). In addition, the MAH is updating sections 4.7 and 4.8 of the SmPC to implement EMA proposed wording and a typo error.
The MAH took the opportunity to update the list of local representatives in the PL and implement minor editorial changes in sections 4.8 and 6.6 of the SmPC and section 2 of the PL.
Furthermore, the PI is brought in line with the latest QRD template version 10.2 rev. 1."

Xolair - omalizumab -
EMEA/H/C/000606/II/0109

Novartis Europharm Limited, Rapporteur: Kristina Dunder, "C.I.4: Update of section 5.1 of the SmPC in order to update information on efficacy and safety based on final results from study WA40169; this is a single-arm, open-label extension study to evaluate the safety, efficacy and durability of response of Xolair in an open-label setting in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP)."

Zejula - niraparib -
EMEA/H/C/004249/II/0032/G, Orphan

GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang, "Submission of the final reports from two non-clinical studies (TSRO/REP/07-08-09 and KB-0139-DV-HB) investigating the carboxylesterase (CE) and UDP-glucuronosyltransferase (UGT) enzymes involved in the metabolism of niraparib."

WS2114
Mekinist-
EMEA/H/C/002643/WS2114/0050
Tafinlar-
EMEA/H/C/002604/WS2114/0054

Novartis Europharm Limited, Lead Rapporteur: Filip Josephson, "Update of section 5.1 of the

SmPC with the final efficacy data from study BRF113928 (CDRB436E2201), conducted in patients with stage IV BRAF V600 mutant NSCLC, in fulfilment of a post-authorisation measure (REC) from the initial MA."	
WS2156 **Nuwiq-EMEA/H/C/002813/WS2156/0047** **Vihuma-** **EMEA/H/C/004459/WS2156/0029** Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus, "Submission of the final report from study GENA-99 including the integrated analysis report of studies GENA-99, GENA-13, GENA-15, GENA-21, GENA-21b and GENA-100. GENA-99 is a Prospective, multinational, non-interventional post-authorisation study to document the long-term immunogenicity, safety, and efficacy of Human-cl rhFVIII (simoctocog alfa) in patients with haemophilia A treated in routine clinical practice."	

B.6.10. CHMP-PRAC assessed procedures

COVID-19 Vaccine Janssen - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0018 Janssen-Cilag International N.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Ulla Wändel Liminga, "Submission of an updated RMP version 2.2 in order to include the following: • To include thrombocytopenia as an important potential risk following the outcome of the signal of Embolic and Thrombotic events (SDA 018.1, EPITT number 19689) and the opinion of procedure EMEA/H/C/005737/II/0006/G • To propose studies aimed at further characterisation of Thrombosis with Thrombocytopenia syndrome (TTS) and thrombocytopenia, following the outcome of the signal of Embolic and Thrombotic events (SDA 018.1, EPITT number 19689) • To include Guillain-Barré syndrome as an important identified risk and update the RMP accordingly (EMEA/H/C/005737/II/0012) In addition, the MAH took the opportunity to update in the EU-RMP the submission milestone	

dates for VAC31518COV4001 and VAC31518COV4002 studies."

Piqray - alpelisib - EMEA/H/C/004804/II/0008/G

Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst, "Update of section 5.1 of the SmPC based on final results from study CBYL719C2301 (SOLAR-1) listed as a PAES in the Annex II; this is a phase III, randomized, double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment; the Annex II is updated accordingly. In addition, the MAH is updating the ATC code in the SmPC. The RMP version 5.0 has also been submitted."

Reagila - cariprazine - EMEA/H/C/002770/II/0023

Gedeon Richter Plc., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ana Sofia Diniz Martins, "Update of sections 4.4, 4.5, 4.6 and 5.2 of the SmPC in order to update pharmacokinetic information based on final results from RGH-188-302 (CAROLA) study listed as a category 3 study in the RMP; this is an open-label, single-arm, fixed-sequence, phase 1 trial in female schizophrenia patients to investigate the effect of multiple-dose administration of cariprazine on the pharmacokinetics of a combined oral contraceptive containing ethinylestradiol and levonorgestrel; the Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to implement minor editorial changes in sections 4.8 and 5.3 of the SmPC and in the PL."

Rubraca - rucaparib - EMEA/H/C/004272/II/0029

Clovis Oncology Ireland Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin, "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on final results from study CO-338-043 (ARIEL4); this is a phase 3, multicentre, open-label, randomised study evaluating the efficacy and safety of rucaparib

versus chemotherapy for treatment of relapsed ovarian cancer listed as a specific obligation in the Annex II; the Package Leaflet is updated accordingly. The RMP version 6.1 has also been submitted. With this variation application, the MAH requests for the Rubraca marketing authorisation to no longer be subject to specific obligations. The SmPC, Annex II and PL are updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes and bring the PI in line with the latest QRD template version 10.2 Rev.1."	
Tremfya - guselkumab - EMEA/H/C/004271/II/0031 Janssen-Cilag International N.V., Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Brigitte Keller-Stanislawski, "C.I.4 Update the sections 4.8 and 5.1 of the SmPC based on based in the 2-year data from the psoriatic arthritis Phase 3 clinical study CNTO1959PSA3002 and to remove this study as an additional PV activity from the EU RMP. The RMP version 8.2 has also been submitted."	
WS2134 OPDIVO- EMEA/H/C/003985/WS2134/0109 Yervoy-EMEA/H/C/002213/WS2134/0091 Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Paula Boudewina van Hennik, Lead PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.2, 4.8 and 5.1 of the SmPC based on final results from study CA209908; this is a Phase Ib/II clinical trial of nivolumab monotherapy and nivolumab in combination with ipilimumab in paediatric subjects with high grade primary CNS malignancies; The RMP version 22.3 for Opdivo has also been submitted."	
WS2153 OPDIVO- EMEA/H/C/003985/WS2153/0111 Yervoy-EMEA/H/C/002213/WS2153/0093 Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Paula Boudewina van Hennik, Lead PRAC Rapporteur: Menno van der Elst, "Update of sections 4.2 and 6.6 of the SmPC to change the infusion time for ipilimumab when used as monotherapy or in combination with nivolumab in the melanoma indications; the Package	

Leaflet for Yervoy is updated accordingly. The RMP versions 34.0 for Yervoy and 26.0 for Opdivo have also been submitted. In addition, an administrative update in Annex II of Yervoy is introduced.”

B.6.11. PRAC assessed procedures

PRAC Led **Afinitor - everolimus - EMEA/H/C/001038/II/0076** Novartis Europharm Limited, Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, “Update of the SmPC section 4.8 to include Lymphoedema as an adverse drug reaction with the frequency common based on the post-marketing data as requested by the PRAC. The PL is updated accordingly.”
PRAC Led **COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0059** BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, “Submission of an updated RMP for COMIRNATY version 2.3 in order to add myocarditis/pericarditis as an important identified risk as per PRAC outcome EMEA/H/C/005735/SDA/032, dated 08. July 2021 (EPITT: 19712). This includes update of the risk minimisation measures related to myocarditis/pericarditis. The MAH is taking the opportunity to update the RMP in line with exposure data at DLP 18 June 2021, the information on planned/ongoing safety studies (protocols C4591011 [US], C4591012 [US], and C4591021 [EU]), the new C4591038 (former C4591021 sub-study) [EU] and inclusion of two new non-interventional US PASS: C4591009 and study C4591036 (former Paediatric Heart Network).”
PRAC Led **COVID-19 Vaccine Janssen - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0020** Janssen-Cilag International N.V., Rapporteur:

Christophe Focke, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Update of sections 4.4 and 4.8 of the SmPC to add a new warning on immune thrombocytopenia (ITP), and to add dizziness and ITP to the list of adverse drug reactions with frequencies uncommon and not know, respectively; based on the PRAC request from EMEA/H/C/005737/MEA/014.3. The package leaflet is updated accordingly."

PRAC Led

Hemlibra - emicizumab - EMEA/H/C/004406/II/0026

Roche Registration GmbH, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ilaria Baldelli, PRAC-CHMP liaison: Armando Genazzani, "Update of section 4.8 of the SmPC to include new data related to hypersensitivity, in compliance with the PRAC recommendation following the assessment of PSUSA/00010668/202011. The PIL is updated in accordance with the changes to the SmPC."

PRAC Led

Moventig - naloxegol - EMEA/H/C/002810/II/0034

Kyowa Kirin Holdings B.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Peter Kiely, "C.I.13: Submission of the final report from the observational Post Authorisation Safety Study (PASS)- Drug Utilisation in Selected European Populations (D3820R00006), listed as a category 3 study in the RMP. The RMP version 7.0 has also been submitted."

PRAC Led

Opsumit - macitentan - EMEA/H/C/002697/II/0042, Orphan

Janssen-Cilag International N.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "Type II C.I.11 variation to update the Risk management plan to v12.1 and to update the Product Information based on the outcome of the PRAC assessment of EMEA/H/C/PSUSA/00010115/202010:
- The controlled distribution system and Prescriber Kit (SmPC, prescribing check list and HCP brochure) is being removed as additional

risk minimisation measures (aRMM) in the RMP and in the product information Annex II.D. Only the patient alert card is remaining as an aRMM. - Off-label use is being removed from the list of safety concerns. - "Elderly patients aged over 75 years", "patients with moderate to severe hepatic impairment" and "Patients with severe renal impairment and/ or undergoing dialysis" are being removed as missing information. - The MAH has also taken the opportunity to include in the RMP Annex 4, the updated Specific Follow-up Questionnaires Forms (pregnancies, menstrual disorders, and ovarian cysts) due to revision of internal company template. In addition, the MAH has taken this opportunity to update the formatting of the headings of the product information (annex I II and III) in line with the latest QRD template."	
PRAC Led **PecFent - fentanyl - EMEA/H/C/001164/II/0054** Kyowa Kirin Holdings B.V., Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of a revised RMP version 7.1 in order, as requested by the PRAC following the assessment of PSUSA 00001369/202004, to update the key messages of the educational materials in line with Instanyl. The Annex IID is updated accordingly. In addition, the MAH took the opportunity to update the RMP format to the GVP revision 2 and implement the latest QRD format in Annex II."	
PRAC Led **Toviaz - fesoterodine - EMEA/H/C/000723/II/0062** Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "Submission of an updated RMP version 10.0 in order to align the important identified risks, important potential risks, and missing information with the new Guideline on good pharmacovigilance practice (GVP) Module V - Risk management systems (Revision 2.0), and to address the PRAC recommendation, dated 26 November 2020, for	

PSUR (EMEA/H/C/PSUSA/00001387/202004). The PRAC recommended that safety in paediatric patients should not be considered per se missing information in the RMP, as well as the important identified and potential risks and missing information and should be removed from the RMP at the next regulatory opportunity."

PRAC Led

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0040

AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Christophe Focke, "Submission of an updated RMP version 4.1 in order to:
- Add 'Thrombosis in combination with thrombocytopenia' as an important potential risk, as per PRAC outcome of Signal Assessment procedure on Immune Thrombocytopenia dated 08 July 2021 (EPITT no: 19678);
- Add Acute Macular neuroretinopathy / Acute Macular outer retinopathy, Paracentral acute middle maculopathy and Parasthesia and dysaesthesia in the list of AESIs, as per PRAC outcome of Signal Assessment procedure on Acute Macular Outer Retinopathy dated 08 July 2021 (EPITT no: 19703);
- Remove the Enhanced active surveillance (EAS) studies D8111R00003 [EU], D8110R00001 [US], D8111C00004 [UK]);
- Update of the important potential risk of `Nervous system disorders, including immune-mediated neurological conditions' to reflect recent label updates regarding Guillain-Barré syndrome (IB/0034), as per PRAC outcome of Vaxzevria 4th Monthly Summary Safety Update (MEA 027.3), dated 26 June 2021;
- Add the UK effectiveness study (D8111R00007), as per CHMP conclusion from MEA 010.1 dated 22 July 2021;
- Addition of a study D8111R00010 to assess the relationship between the exposure to COVID-19 vaccines and risk of thrombotic thrombocytopenia syndrome."

PRAC Led

XGEVA - denosumab - EMEA/H/C/002173/II/0078

Amgen Europe B.V., Rapporteur: Kristina

Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report from study 20101102 "Osteonecrosis of the Jaw (ONJ) Case Registry", listed as a category 3 study in the RMP. This is an observational PASS with the primary objective to estimate the rate and describe the time course of resolution of ONJ, in subjects 18 years of age with cancer who had newly diagnosed, positively adjudicated ONJ."

PRAC Led

Zostavax - varicella vaccine (live) - EMEA/H/C/000674/II/0138

MSD Vaccins, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of an updated RMP version 9.1 to reflect the completion of this long-term effectiveness study (Protocol 024) and to align the RMP template with EMA GVP Module V (rev 2) guidance."

PRAC Led

WS2151 Aflunov- EMEA/H/C/002094/WS2151/0071 Foclivia- EMEA/H/C/001208/WS2151/0068

Seqirus S.r.l, Lead Rapporteur: Armando Genazzani, Lead PRAC Rapporteur: Ilaria Baldelli, PRAC-CHMP liaison: Armando Genazzani, "Submission of an updated RMP version 3.9 in order to align safety concerns for both products AFLUNOV and FOCLIVIA. Module on 'Epidemiology of the indication and target population' and section on 'use in pregnancy and lactation' are updated. Some potential risks have been reclassified following the definition as per GVP Module V rev.2. Reference to adverse drug reaction follow-up forms for routine pharmacovigilance activity are removed."

B.6.12. CHMP-CAT assessed procedures

Abecma - idecabtagene vicleucel - EMEA/H/C/004662/II/0001/G, Orphan, ATMP

Celgene Europe B.V., Rapporteur: Rune Kjeken, CHMP Coordinator: Johanna Lähteenvuo
Abecma - idecabtagene vicleucel - EMEA/H/C/004662/II/0002, Orphan, ATMP Celgene Europe B.V., Rapporteur: Rune Kjeken, CHMP Coordinator: Johanna Lähteenvuo
Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0047/G, ATMP Amgen Europe B.V., Rapporteur: Heli Suila, CHMP Coordinator: Johanna Lähteenvuo
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0019/G, Orphan, ATMP Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2088/G **Brimica Genuair- EMEA/H/C/003969/WS2088/0033/G** **Duaklir Genuair- EMEA/H/C/003745/WS2088/0033/G** AstraZeneca AB, Lead Rapporteur: Ewa Balkowiec Iskra
WS2096 **Comtess- EMEA/H/C/000170/WS2096/0061** **Entacapone Orion- EMEA/H/C/002440/WS2096/0020** Orion Corporation, Lead Rapporteur: Outi Mäki-Ikola, "To update sections 2 and 4.4. of the SmPC, section 3 of the Labelling and section 2 of the PL to add a statement warning for the excipient sodium. The proposed update is not in accordance with the Annex of the "Excipients in the labelling and package leaflet of medicinal products". The marketing authorisation holder took the

opportunity to align the PI to the latest QRD template (version 10.2). The details of the local representatives are updated for Comtess in United Kingdom (Northern Ireland) and for Entacapone Orion in Germany, Greece, Ireland, Poland and United Kingdom (Northern Ireland)."	
WS2128/G **Eucreas-** **EMEA/H/C/000807/WS2128/0090/G** **Icandra-** **EMEA/H/C/001050/WS2128/0093/G** **Zomarist-** **EMEA/H/C/001049/WS2128/0092/G** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder	
WS2137 **Relvar Ellipta-** **EMEA/H/C/002673/WS2137/0050** **Revinty Ellipta-** **EMEA/H/C/002745/WS2137/0048** GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro	
WS2143 **HBVAXPRO-** **EMEA/H/C/000373/WS2143/0072** **Vaxelis-EMEA/H/C/003982/WS2143/0089** MCM Vaccine B.V., Lead Rapporteur: Christophe Focke	
WS2157 **Epclusa-** **EMEA/H/C/004210/WS2157/0062** **Harvoni-** **EMEA/H/C/003850/WS2157/0102** **Sovaldi-EMEA/H/C/002798/WS2157/0076** **Vosevi-EMEA/H/C/004350/WS2157/0049** Gilead Sciences Ireland UC, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, "To update the due date for the hepatocellular carcinoma (HCC) recurrence post authorisation safety study (PASS) in Annex II of the PI."	
WS2167 **Aflunov-** **EMEA/H/C/002094/WS2167/0073** **Foclivia-** **EMEA/H/C/001208/WS2167/0070** Seqirus S.r.l, Lead Rapporteur: Armando	

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. Timetables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 13-16 September 2021 CHMP plenary:

Neurology	
Treatment of cluster headache	The CHMP denied eligibility to PRIME and adopted the critical summary report.
TAK-994Treatment of narcolepsy with cataplexy	The CHMP granted eligibility to PRIME and adopted the critical summary report.
Treatment of early symptomatic Alzheimer's disease	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Oncology	
Treatment of cutaneous T-cell lymphoma (CTCL) (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Ophtalmology	
Treatment of retinitis pigmentosa due to mutations in exon 13 of the USH2A gene (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.

G.2.2. List of procedures starting in September 2021 for October 2021 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address